<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000332.pub3" GROUP_ID="MUSKEL" ID="359699082413045394" MERGED_FROM="" MODIFIED="2015-02-18 14:28:59 +0000" MODIFIED_BY="Jordi Pardo Pardo" REVIEW_NO="C122-R" REVMAN_SUB_VERSION="5.2.8 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2015-02-18 14:28:59 +0000" MODIFIED_BY="Jordi Pardo Pardo">
<TITLE MODIFIED="2010-02-15 21:10:48 -0430" MODIFIED_BY="[Empty name]">Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis</TITLE>
<CONTACT MODIFIED="2015-02-18 14:28:59 +0000" MODIFIED_BY="Jordi Pardo Pardo"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="VE">Venezuela</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-02-18 14:28:59 +0000" MODIFIED_BY="Jordi Pardo Pardo"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><COUNTRY CODE="VE">Venezuela</COUNTRY></ADDRESS></PERSON><PERSON ID="3329B2B182E26AA200CD32E57C3A2C53" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Luis</FIRST_NAME><MIDDLE_INITIALS>H</MIDDLE_INITIALS><LAST_NAME>Agreda-Pérez</LAST_NAME><EMAIL_1>maria.agreda@cindu.com.ve</EMAIL_1><ADDRESS><DEPARTMENT>Medicina Interna</DEPARTMENT><ORGANISATION>Hospital "Dr. Adolfo Prince Lara"</ORGANISATION><ADDRESS_1>Av. Salom</ADDRESS_1><CITY>Pto. Cabello</CITY><REGION>Edo. Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58 242 62 1033</PHONE_1><PHONE_2>+58 412 531 0376</PHONE_2><FAX_1>+58 242 62 1857</FAX_1></ADDRESS></PERSON><PERSON ID="12177" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Ivan</FIRST_NAME><LAST_NAME>Solà</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>isola@santpau.cat</EMAIL_1><EMAIL_2>ensayos@cochrane.es</EMAIL_2><ADDRESS><DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT><ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION><ADDRESS_1>Sant Antoni Maria Claret 171 - Edifici Casa de Convalescència</ADDRESS_1><CITY>Barcelona</CITY><ZIP>08041</ZIP><REGION>Catalunya</REGION><COUNTRY CODE="ES">Spain</COUNTRY><PHONE_1>+34 932 919 527</PHONE_1><FAX_1>+34 932 919 525</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-02-25 19:36:36 -0430" MODIFIED_BY="Arturo Martí-Carvajal">
<UP_TO_DATE>
<DATE DAY="11" MONTH="8" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="8" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="11" MONTH="8" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2013"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2013"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-24 13:29:02 -0430" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-24 13:29:02 -0430" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>Change of authorship and new contact person. Criteria for inclusion and methods updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-11-22 12:18:59 -0430" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-05 15:35:05 -0430" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>The protocol has been changed from all sections.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-05 15:35:09 -0430" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>CMSG ID: C122-P</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-02-15 21:13:48 -0430" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2012-11-22 16:16:24 -0430" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2012-11-22 16:16:24 -0430" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-01-20 17:00:22 -0430" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Centre</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2012-03-02 13:51:51 -0430" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Musculoskeletal Group</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION>
<P>Academic.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-22 16:14:30 -0430" MODIFIED_BY="Kate Cahill">
<SUMMARY MODIFIED="2013-01-21 13:22:46 -0430" MODIFIED_BY="Kate Cahill">
<TITLE MODIFIED="2011-12-07 11:48:14 -0430" MODIFIED_BY="[Empty name]">Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis</TITLE>
<SUMMARY_BODY MODIFIED="2013-01-21 13:22:46 -0430" MODIFIED_BY="Kate Cahill">
<P>Researchers in the Cochrane Collaboration conducted a review of the effect of erythropoiesis-stimulating agents for anemia in patients with rheumatoid arthritis.  After searching for all relevant studies, they found three studies covering 133 people. Their findings are summarised below:</P>
<P>The review shows that in people with anemia and rheumatoid arthritis:</P>
<P>- it is uncertain whether erythropoiesis-stimulating agents improve quality of life or hemoglobin levels.<BR/>- it is unknown whether erythropoiesis-stimulating agents improve fatigue, as this was not measured by the studies.</P>
<P>We do not have precise information about side effects and complications. This is particularly true for rare but serious side effects, which may include thromboembolic complications. </P>
<P>
<B>What is anemia in rheumatoid arthritis and what are erythropoiesis-stimulating agents? </B>
<BR/>
</P>
<P>When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints. This makes them swollen, stiff and painful. The small joints of the hands and feet are usually affected first.  As the disease progresses, other complications may appear, including anemia (low hemoglobin level). Hemoglobin is a protein in red blood cells that carries oxygen.  Anemia is a condition in which the body does not have enough healthy red blood cells.  Erythropoietin is a hormone produced in the kidney, which increases the production of red blood cells. Erythropoiesis-stimulating agents work to increase red blood cell production. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-21 15:22:26 -0430" MODIFIED_BY="Kate Cahill">
<ABS_BACKGROUND MODIFIED="2013-01-21 12:42:20 -0430" MODIFIED_BY="Kate Cahill">
<P>Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disorder that mainly affects the small joints of the hands and feet. Erythropoiesis-stimulating agents have been used to treat anemia, one of the extra-articular manifestations of RA. Although anemia is less of a problem now because of the reduction in inflammation due to disease-modifying antirheumatic drugs (DMARDs), it could still be an issue in countries where DMARDs are not yet accessible.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-11-22 16:05:08 -0430" MODIFIED_BY="[Empty name]">
<P>We assessed the clinical benefits and harms of erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-21 12:42:49 -0430" MODIFIED_BY="Kate Cahill">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> (issue 7 2012), Ovid MEDLINE and Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations (1948 to 7 August 2012), OVID EMBASE (1980 to 7 August 2012), LILACS (1982 to 7 August 2012), the Clinical Trials Search Portal of the World Health Organization, reference lists of the retrieved publications and review articles. We did not apply any language restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-01-21 15:22:26 -0430" MODIFIED_BY="Kate Cahill">
<P>We included randomized controlled trials (RCTs) in patients aged 16 years or over, with a diagnosis of rheumatoid arthritis affected by anemia. We considered health-related quality of life, fatigue and safety as the primary outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-01-21 12:43:46 -0430" MODIFIED_BY="Kate Cahill">
<P>Two authors independently performed trial selection, risk of bias assessment, and data extraction. We estimated difference in means with 95% confidence intervals (CIs) for continuous outcomes. We estimated risk ratios with 95% CIs for binary outcomes. 
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-01-21 12:49:58 -0430" MODIFIED_BY="Kate Cahill">
<P>We included three RCTs with a total of 133 participants. All trials compared human recombinant erythropoietin (EPO), for different durations (8, 12 and 52 weeks), versus placebo. All RCTs assessed health-related quality of life. All trials had high or unclear risk of bias for most domains, and were sponsored by the pharmaceutical industry. Two trials administered EPO by a subcutaneous route while the other used an intravenous route. </P>
<P>We decided not to pool results from trials, due to inconsistencies in the reporting of results.</P>
<P>Health-related quality of life: subcutaneous EPO &#8211; one trial with 70 patients at 52 weeks showed a statistically significant difference in improvement of patient global assessment (median and interquartile range 3.5 (1.0 to 6.0) compared with placebo 4.5 (2.0 to 7.5) (P = 0.027) on a VAS scale (0 to 10)). The other shorter term trials (12 weeks with subcutaneous EPO and eight weeks with intravenous administration) did not find statistically significant differences between treatment and control groups in health-related quality of life outcomes.</P>
<P>Change in hemoglobin: both trials of subcutaneous EPO showed a statistically significant difference in increasing hemoglobin levels; (i) at  52 weeks (one trial, 70 patients), intervention hemoglobin level (median 134, interquartile range 110 to 158 g/litre) compared with the placebo group level (median 112, interquartile range; 86 to 128 g/litre) (P = 0.0001); (ii) at  12 weeks (one trial, 24 patients) compared with placebo (difference in means 8.00, 95% CI 7.43 to 8.57). Intravenous EPO at eight weeks showed no statistically significant difference in increasing hematocrit level for EPO versus placebo (difference in means 4.69, 95% CI -0.17 to 9.55; P = 0.06).</P>
<P>Information on withdrawals due to adverse events was not reported in two trials, and one trial found no serious adverse events leading to withdrawals. None of the trials reported withdrawals due to high blood pressure, or to lack of efficacy or to fatigue.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-21 12:51:53 -0430" MODIFIED_BY="Kate Cahill">
<P>We found conflicting evidence for erythropoiesis-stimulating agents to increase quality of life and hemoglobin level by treating anemia in patients with rheumatoid arthritis. However, this conclusion is based on randomized controlled trials with a high risk of bias, and relies on trials assessing human recombinant erythropoietin (EPO). The safety profile of EPO is unclear. Future trials assessing erythropoiesis-stimulating agents for anemia in rheumatoid arthritis should be conducted by independent researchers and reported according to the CONSORT statements. Trials should be based on Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) and The Patient-Centered Outcomes Research Institute (PCORI) approaches for combining both clinician and patient perspectives.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-22 16:14:30 -0430" MODIFIED_BY="Kate Cahill">
<BACKGROUND MODIFIED="2013-01-21 13:41:03 -0430" MODIFIED_BY="Kate Cahill">
<CONDITION MODIFIED="2013-01-21 13:31:24 -0430" MODIFIED_BY="Kate Cahill">
<SUBSECTION>
<HEADING LEVEL="4">The burden of anemia in rheumatoid arthritis</HEADING>
<P>Rheumatoid arthritis is a chronic and systemic inflammatory disorder that mainly affects the small joints of the hands and feet (<LINK REF="REF-Lee-2001" TYPE="REFERENCE">Lee 2001</LINK>). The criteria for the classification of rheumatoid arthritis are described in <LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK> (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). Recently, the immunopathogenesis of rheumatoid arthritis has been described (<LINK REF="REF-Imboden-2009" TYPE="REFERENCE">Imboden 2009</LINK>; <LINK REF="REF-McInnes-2011" TYPE="REFERENCE">McInnes 2011</LINK>). Rheumatoid arthritis has variable extra-articular manifestations which are known as comorbidities (<LINK REF="REF-Grassi-1998" TYPE="REFERENCE">Grassi 1998</LINK>; <LINK REF="REF-Hochberg-2008" TYPE="REFERENCE">Hochberg 2008</LINK>; <LINK REF="REF-Michaud-2007" TYPE="REFERENCE">Michaud 2007</LINK>; <LINK REF="REF-Turesson-2003" TYPE="REFERENCE">Turesson 2003</LINK>; <LINK REF="REF-Young-2007" TYPE="REFERENCE">Young 2007</LINK>). Anemia is one of those comorbidities (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), and this has a prevalence ranging from 33% to 60% (<LINK REF="REF-Al_x002d_Ghamdi-2009" TYPE="REFERENCE">Al-Ghamdi 2009</LINK>; <LINK REF="REF-Furst-2009" TYPE="REFERENCE">Furst 2009</LINK>; <LINK REF="REF-Wilson-2004" TYPE="REFERENCE">Wilson 2004</LINK>). According to the World Health Organization, hemoglobin thresholds used to define anemia are 120 g/L for non-pregnant women (&#8805;15 years old) and 130 g/L for men (&#8805;15 years old) (<LINK REF="REF-WHO-2008" TYPE="REFERENCE">WHO 2008</LINK>). However, anemia is less of a problem now because of the reduction in inflammation due to disease-modifying antirheumatic drugs (DMARDs) (<LINK REF="REF-Blumenauer-2002" TYPE="REFERENCE">Blumenauer 2002</LINK>; <LINK REF="REF-Blumenauer-2003" TYPE="REFERENCE">Blumenauer 2003</LINK>; <LINK REF="REF-Maxwell-2009" TYPE="REFERENCE">Maxwell 2009</LINK>; <LINK REF="REF-Mertens-2009" TYPE="REFERENCE">Mertens 2009</LINK>; <LINK REF="REF-Navarro_x002d_Sarabia-2005" TYPE="REFERENCE">Navarro-Sarabia 2005</LINK>; <LINK REF="REF-Ruiz-Garcia-2011" TYPE="REFERENCE">Ruiz Garcia 2011</LINK>; <LINK REF="REF-Singh-2009" TYPE="REFERENCE">Singh 2009</LINK>; <LINK REF="REF-Singh-2010a" TYPE="REFERENCE">Singh 2010a</LINK>; <LINK REF="REF-Singh-2010b" TYPE="REFERENCE">Singh 2010b</LINK>; <LINK REF="REF-Singh-2011" TYPE="REFERENCE">Singh 2011</LINK>), but it can still be an issue in countries where the drugs are not yet accessible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Why do patients with rheumatoid arthritis have anemia?</HEADING>
<P>Rheumatoid arthritis is a chronic inflammatory state characterized by high circulating levels of interleukin-6 (IL-6) (<LINK REF="REF-Cronstein-2007" TYPE="REFERENCE">Cronstein 2007</LINK>; <LINK REF="REF-Dayer-2010" TYPE="REFERENCE">Dayer 2010</LINK>; <LINK REF="REF-Fonseca-2009" TYPE="REFERENCE">Fonseca 2009</LINK>; <LINK REF="REF-Kishimoto-2006" TYPE="REFERENCE">Kishimoto 2006</LINK>; <LINK REF="REF-Nicolaisen-2008" TYPE="REFERENCE">Nicolaisen 2008</LINK>). IL-6 stimulates the hepatic production of hepcidin (<LINK REF="REF-Dayer-2010" TYPE="REFERENCE">Dayer 2010</LINK>; <LINK REF="REF-Ganz-2009" TYPE="REFERENCE">Ganz 2009</LINK>; <LINK REF="REF-Raj-2009" TYPE="REFERENCE">Raj 2009</LINK>; <LINK REF="REF-Zhang-2009" TYPE="REFERENCE">Zhang 2009</LINK>), which is the main iron regulatory hormone (<LINK REF="REF-Andrews-2007" TYPE="REFERENCE">Andrews 2007</LINK>; <LINK REF="REF-Andrews-2008" TYPE="REFERENCE">Andrews 2008</LINK>; <LINK REF="REF-Lee-2009" TYPE="REFERENCE">Lee 2009</LINK>; <LINK REF="REF-Mu_x00f1_oz-2009" TYPE="REFERENCE">Muñoz 2009</LINK>; <LINK REF="REF-Nemeth-2003" TYPE="REFERENCE">Nemeth 2003</LINK>; <LINK REF="REF-Sasu-2010" TYPE="REFERENCE">Sasu 2010</LINK>). This hormone causes inhibition of iron release from macrophages which generates iron sequestration (<LINK REF="REF-Ganz-2009" TYPE="REFERENCE">Ganz 2009</LINK>; <LINK REF="REF-Nemeth-2004" TYPE="REFERENCE">Nemeth 2004</LINK>). It reduces the iron supply to erythropoiesis-generating anemia called 'anemia of inflammation', which shows the interplay between iron and immune function (<LINK REF="REF-Demirag-2009" TYPE="REFERENCE">Demirag 2009</LINK>; <LINK REF="REF-Ganz-2009" TYPE="REFERENCE">Ganz 2009</LINK>; <LINK REF="REF-Jayaranee-2009" TYPE="REFERENCE">Jayaranee 2009</LINK>; <LINK REF="REF-Roy-2005" TYPE="REFERENCE">Roy 2005</LINK>; <LINK REF="REF-Weiss-2009" TYPE="REFERENCE">Weiss 2009</LINK>). This anemia is also known as 'anemia of chronic disease' (<LINK REF="REF-Agarwal-2009" TYPE="REFERENCE">Agarwal 2009</LINK>; <LINK REF="REF-Cartwright-1966" TYPE="REFERENCE">Cartwright 1966</LINK>; <LINK REF="REF-Means-1995" TYPE="REFERENCE">Means 1995</LINK>; <LINK REF="REF-Theurl-2009" TYPE="REFERENCE">Theurl 2009</LINK>; <LINK REF="REF-Masson-2011" TYPE="REFERENCE">Masson 2011</LINK>). The term 'anemia of inflammation' reflects its pathophysiology (<LINK REF="REF-Ganz-2009" TYPE="REFERENCE">Ganz 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other factors for explaining the pathogenesis of anemia in rheumatoid arthritis</HEADING>
<P>Anemia in rheumatoid arthritis due to serum immunoreactive erythropoietin has been described (<LINK REF="REF-Hochberg-1988" TYPE="REFERENCE">Hochberg 1988</LINK>), and lower levels of serum erythropoietin in these patients may contribute to the pathogenesis of anemia (<LINK REF="REF-Baer-1997" TYPE="REFERENCE">Baer 1997</LINK>). Furthermore, tumour necrosis factor alpha, interleukin-1 (IL-1), and interferon-gamma (IFN-gamma) are factors mediating impaired erythropoiesis in anemia of chronic disease in active rheumatoid arthritis (<LINK REF="REF-Capocasale-2008" TYPE="REFERENCE">Capocasale 2008</LINK>; <LINK REF="REF-Moreland-2009" TYPE="REFERENCE">Moreland 2009</LINK>; <LINK REF="REF-Papadaki-2002" TYPE="REFERENCE">Papadaki 2002</LINK>; <LINK REF="REF-Smith-1992" TYPE="REFERENCE">Smith 1992</LINK>; <LINK REF="REF-Vreugdenhil-1992a" TYPE="REFERENCE">Vreugdenhil 1992a</LINK>; <LINK REF="REF-Zhu-2000" TYPE="REFERENCE">Zhu 2000</LINK>). Patients with rheumatoid arthritis and suffering with anemia have a decreased sensitivity of bone marrow erythroblasts to interleukin-3, which has hematopoietic growth-promoting activity (<LINK REF="REF-Jaworski-2008" TYPE="REFERENCE">Jaworski 2008</LINK>; <LINK REF="REF-Wu-2003" TYPE="REFERENCE">Wu 2003</LINK>). In summary, the pathophysiology of anemia in rheumatoid arthritis involves three mechanisms: disturbances of iron homeostasis, inhibition of erythroid progenitor of proliferation and differentiation, and blunted erythropoietin response (<LINK REF="REF-Weiss-2002" TYPE="REFERENCE">Weiss 2002</LINK>).<BR/>
</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2013-01-21 13:38:33 -0430" MODIFIED_BY="Kate Cahill">
<P>Erythropoietin is a glycoprotein hormone that is produced in the kidney and acts through specific receptors on hematopoietic precursor cells to increase the production of red blood cells (<LINK REF="REF-Glaspy-2009" TYPE="REFERENCE">Glaspy 2009</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Erythropoiesis-Stimulating Agents (ESAs)</HEADING>
<P>There are two types of erythropoiesis-stimulating agents: recombinant human erythropoietin (alpha and beta) and darbepoetin alpha. Recombinant human erythropoietin is a hemopoietic growth factor that acts as a primary regulator of erythropoiesis. It is used for the treatment of chronic anemia associated with rheumatoid arthritis (<LINK REF="REF-Coussons-2005" TYPE="REFERENCE">Coussons 2005</LINK>). Darbepoetin alpha is an analogue of recombinant human erythropoietin. Both agents share the same mechanism of action, but darbepoetin alpha has a three-fold longer terminal half-life (25.3 hours), after intravenous administration, than recombinant human erythropoietin (8.5 hours) (<LINK REF="REF-Cases-2003" TYPE="REFERENCE">Cases 2003</LINK>; <LINK REF="REF-Ibbotson--2001" TYPE="REFERENCE">Ibbotson 2001</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<IMPORTANCE MODIFIED="2013-01-21 13:41:03 -0430" MODIFIED_BY="Kate Cahill">
<P>There are randomized controlled trials (<LINK REF="STD-Murphy-1994" TYPE="STUDY">Murphy 1994</LINK>; <LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>), clinical trials (<LINK REF="STD-Arndt-2005" TYPE="STUDY">Arndt 2005</LINK>; <LINK REF="STD-Fantini-1992" TYPE="STUDY">Fantini 1992</LINK>; <LINK REF="REF-Gudbj_x00f6_rnsson-1992" TYPE="REFERENCE">Gudbjörnsson 1992</LINK>; <LINK REF="STD-Kaltwasser-2001" TYPE="STUDY">Kaltwasser 2001</LINK>; <LINK REF="STD-Kato-1994" TYPE="STUDY">Kato 1994</LINK>; <LINK REF="REF-Pettersson-1993" TYPE="REFERENCE">Pettersson 1993</LINK>; <LINK REF="REF-Pettersson-1994" TYPE="REFERENCE">Pettersson 1994</LINK>; <LINK REF="STD-Salvarani-1991" TYPE="STUDY">Salvarani 1991</LINK>; <LINK REF="STD-Swaak-1994" TYPE="STUDY">Swaak 1994</LINK>; <LINK REF="STD-Takashina-1990" TYPE="STUDY">Takashina 1990</LINK>; <LINK REF="STD-Tauchi-1990" TYPE="STUDY">Tauchi 1990</LINK>; <LINK REF="REF-Vreugdenhil-1992b" TYPE="REFERENCE">Vreugdenhil 1992b</LINK>) and case reports (<LINK REF="REF-Krantz-1990" TYPE="REFERENCE">Krantz 1990</LINK>; <LINK REF="STD-Means-1989" TYPE="STUDY">Means 1989</LINK>) using human recombinant erythropoietin for treating anemia in rheumatoid arthritis. However, this drug was not approved for this indication.<BR/>
<BR/>This systematic review is important for the following issues.<BR/>1. Anemia is a comorbidity with negative impact on quality of life in patients with rheumatoid arthritis (<LINK REF="REF-Han-2007" TYPE="REFERENCE">Han 2007</LINK>; <LINK REF="REF-Michaud-2007" TYPE="REFERENCE">Michaud 2007</LINK>). Low hemoglobin levels may be associated with rheumatoid arthritis disease severity and the presence of certain comorbidities (<LINK REF="REF-Furst-2009" TYPE="REFERENCE">Furst 2009</LINK>).<BR/>2. Anemia is associated with the severity of rheumatoid arthritis, and its successful treatment leads to a significant improvement in the quality of life scores in patients with rheumatoid arthritis (<LINK REF="REF-Wilson-2004" TYPE="REFERENCE">Wilson 2004</LINK>).<BR/>3. The clinical effectiveness of erythropoiesis-stimulating agents could be affected (hyporesponsiveness to erythropoietic therapy) by chronic inflammation (<LINK REF="REF-Macdougall-2005" TYPE="REFERENCE">Macdougall 2005</LINK>; <LINK REF="REF-van-der-Putten-2008" TYPE="REFERENCE">van der Putten 2008</LINK>).<BR/>4. Erythropoiesis-stimulating agents have been associated with an increased risk of mortality and cardiovascular events in cancer patients (<LINK REF="REF-Bennet-2008" TYPE="REFERENCE">Bennet 2008</LINK>; <LINK REF="REF-Hershman-2009" TYPE="REFERENCE">Hershman 2009</LINK>), and in patients with chronic kidney disease (<LINK REF="REF-Unger-2010" TYPE="REFERENCE">Unger 2010</LINK>). Both erythropoiesis-stimulating agents have been labelled with a warning by the Food and Drug Administration due to the following adverse events: increased mortality, serious cardiovascular and thromboembolic events, and increased risk of tumor progression or recurrence (<LINK REF="REF-FDA-2008a" TYPE="REFERENCE">FDA 2008a</LINK>; <LINK REF="REF-FDA-2008b" TYPE="REFERENCE">FDA 2008b</LINK>).</P>
<P>A systematic review, with rigorous assessment of the risk of bias, of the most up-to-date evidence will help clinicians make informed decisions about the use of erythropoiesis-stimulating agents for treating anemia in patients with rheumatoid arthritis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-01-21 13:41:06 -0430" MODIFIED_BY="[Empty name]">
<P>To assess the clinical benefits and harms of erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-22 16:12:38 -0430" MODIFIED_BY="Kate Cahill">
<SELECTION_CRITERIA MODIFIED="2013-01-21 15:22:51 -0430" MODIFIED_BY="Kate Cahill">
<CRIT_STUDIES MODIFIED="2013-01-21 13:41:21 -0430" MODIFIED_BY="Kate Cahill">
<P>We included randomized controlled trials irrespective of their publication status, language and country of origin. We included trials irrespective of their follow-up duration.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-01-21 15:22:51 -0430" MODIFIED_BY="Kate Cahill">
<P>We included patients aged 16 years and older, with a diagnosis of rheumatoid arthritis and affected by anemia.</P>
<OL>
<LI>Diagnosis of rheumatoid arthritis was based on the American College of Rheumatology criteria (ACR) (<LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK>). See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
</LI>
<LI>Diagnosis of anemia was based on the World Health Organization (WHO) criteria. See <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</LI>
</OL>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-01-21 13:43:28 -0430" MODIFIED_BY="Kate Cahill">
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>Erythropoiesis-stimulating agents (epoetin (alpha or beta) or darbepoetin alpha) alone or in combination with oral or parenteral iron supplementation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control</HEADING>
<OL>
<LI>Epoetin alpha compared with epoetin beta.</LI>
<LI>Darbepoetin alpha versus epoetin (alpha or beta).</LI>
<LI>Epoetin alpha or beta versus placebo or no medication.</LI>
<LI>Darbepoetin alpha versus placebo or no medication.</LI>
<LI>Any of the erythropoiesis-stimulating agents versus standard treatment of anemia (Hematinics - iron, folic acid, packed red cell blood transfusion, or both).</LI>
<LI>Any of the erythropoiesis-stimulating agents plus iron, folic acid, or both, versus placebo or versus standard treatment of anemia.</LI>
</OL>
<P>We accepted as potentially eligible any trials that assessed any erythropoiesis-stimulating agents regimen, in terms of route of administration (intravenous or subcutaneous), dosage, or treatment duration. We included trials that used hematinics as co-interventions, administered by any route, dosage or treatment duration.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-01-21 13:44:07 -0430" MODIFIED_BY="Kate Cahill">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-01-21 13:44:07 -0430" MODIFIED_BY="Kate Cahill">
<OL>
<LI>Health-related quality of life: &#8220;the degree to which persons perceive themselves able to function physically, emotionally, mentally, and socially&#8221; (<LINK REF="REF-Porta-2008" TYPE="REFERENCE">Porta 2008</LINK>). To be included in the review, trials had to use standardized scales (e.g. European League Against Rheumatism (EULAR), Disease Activity Score (DAS28), Health Assessment Questionnaire Disability Index (HAQ-DI), Routine Assessment of Patient Index Data 3 (RAPID3), Clinical Disease Activity Index (CDAI)).</LI>
<LI>Fatigue (<LINK REF="REF-Kirwan-2007" TYPE="REFERENCE">Kirwan 2007</LINK>).</LI>
<LI>Safety:</LI>
</OL>
<UL>
<LI>
<I>Adverse events</I>: "any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment" (<LINK REF="REF-Nebeker-2004" TYPE="REFERENCE">Nebeker 2004</LINK>);</LI>
</UL>
<UL>
<LI>
<I>Adverse drug reactio</I>n: "a response to a drug which is noxious and uninitiated and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiologic functions" (<LINK REF="REF-Nebeker-2004" TYPE="REFERENCE">Nebeker 2004</LINK>). (e.g. high blood pressure).</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-07-27 10:34:51 -0430" MODIFIED_BY="[Empty name]">
<OL>
<LI>Hemoglobin (Hb) level at the end of the study.</LI>
<LI>Withdrawals due to adverse events.</LI>
<LI>Withdrawals due to lack of efficacy.</LI>
<LI>Withdrawals due to high blood pressure. 
</LI>
<LI>Withdrawals due to high disease activity.</LI>
<LI>Withdrawals due to poor compliance.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-21 13:49:15 -0430" MODIFIED_BY="Kate Cahill">
<ELECTRONIC_SEARCHES MODIFIED="2013-01-21 13:49:00 -0430" MODIFIED_BY="Kate Cahill">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library </I>(issue 7, 2012), Ovid MEDLINE and Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations (1948 to 7 August 2012), OVID EMBASE (1980 to 17 August 2012), and LILACS (1982 to 7 August 2012). See <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>; <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>; <LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>; <LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK> for full search strategies.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-01-21 13:49:15 -0430" MODIFIED_BY="Kate Cahill">
<P>We searched the Clinical Trials Search Portal of the World Health Organization (<A HREF="https://mailuio.ute.edu.ec/owa/redir.aspx?C=02d9f51d86d14455bc613f730127e4e4&amp;URL=http%3a%2f%2fapps.who.int%2ftrialsearch%2f">http://apps.who.int/trialsearch/</A>) to identify ongoing and unpublished trials.</P>
<P>We also searched the reference lists of the retrieved publications and review articles. We did not apply any language restrictions.</P>
<P>Date of the most recent search: 7 August 2012.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-01-22 16:12:38 -0430" MODIFIED_BY="Kate Cahill">
<STUDY_SELECTION MODIFIED="2013-01-21 13:49:50 -0430" MODIFIED_BY="Kate Cahill">
<P>AMC and DS screened the search results for potentially relevant trials, and assessed them independently. They resolved disagreements through discussion with LAP and IS to reach a consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-01-21 13:50:44 -0430" MODIFIED_BY="Kate Cahill">
<P>AMC and DS extracted the data using the agreed form, and resolved discrepancies through discussion. IS checked the data entered into Review Manager 5 (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) for accuracy.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-01-21 13:54:22 -0430" MODIFIED_BY="Kate Cahill">
<P>All review authors independently assessed the risk of bias for each included trial, using the domain-based evaluation as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). All review authors checked the assessments, discussed discrepancies and achieved consensus.</P>
<P>The definition of each domain classification is given below:</P>
<P>
<B>Generation of allocation sequence (checking for possible selection bias)</B>
</P>
<UL>
<LI>Low risk of bias, if the allocation sequence was generated by a computer or random number table, drawing of lots, tossing of a coin, shuffling of cards, or throwing dice.</LI>
<LI>Unclear risk of bias, if the trial was described as randomized but the method used for the allocation sequence generation was not described.</LI>
<LI>High risk of bias, if a system involving dates, names, or admittance numbers was used for the allocation of patients. These studies are known as quasi-randomized and were excluded from the present review when assessing beneficial effects.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Allocation concealment (checking for possible selection bias)</HEADING>
<UL>
<LI>Low risk of bias, if the allocation of patients involved a central independent unit, on-site locked computer, identical-appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI>Unclear risk of bias, if the trial was described as randomized but the method used to conceal the allocation was not described.</LI>
<LI>High risk of bias, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomized. The latter was excluded from the present review when assessing beneficial effects.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Blinding or masking (checking for possible performance or detection bias)</HEADING>
<P>We assessed the adequacy of blinding separately for participants, carers/personnel and outcome assessors.</P>
<UL>
<LI>Low risk of bias: participants, carers/personnel and/or outcome assessors blinded from knowledge of which intervention the participant received, or the lack of blinding could not have affected the results;</LI>
<LI>High risk of bias: participants, carers/personnel and/or outcome assessors were not blinded from the knowledge of which intervention the participant received and this could have affected the results;</LI>
<LI>Unclear risk of bias: the blinding of participants, carers/personnel and outcome assessors was not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<UL>
<LI>Low risk of bias (any one of the following): No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</LI>
</UL>
<UL>
<LI>High risk of bias (any one of the following): reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomizations; potentially inappropriate application of simple imputation.</LI>
</UL>
<UL>
<LI>Unclear risk of bias (any one of the following): insufficient reporting of attrition/exclusions to permit judgement of &#8216;low risk&#8217; or &#8216;high risk&#8217; (e.g. number randomized not stated, no reasons for missing data provided); the study did not address this outcome.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Selective reporting bias (Outcome reporting bias)</HEADING>
<UL>
<LI>Low risk of bias (any one of the following): the study protocol is available and all the pre-specified (primary and secondary) outcomes were reported in the final report, or the study protocol was not available but it was clear that the published reports included all expected outcomes.</LI>
<LI>High risk of bias (any one of the following): not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</LI>
<LI>Unclear risk of bias insufficient information available to permit judgement of &#8216;Low risk&#8217; or &#8216;High risk&#8217;.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other bias</HEADING>
<UL>
<LI>Low risk of bias, the trial appeared to be free of other components that could put it at risk of bias.</LI>
<LI>Unclear risk of bias, the trial may or may not be free of other components that could put it at risk of bias.</LI>
<LI>High risk of bias, there were other factors in the trial that could put it at risk of bias.</LI>
</UL>
<P>AMC entered the data into RevMan 5, and DS and IS checked them. </P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-01-21 13:55:38 -0430" MODIFIED_BY="Kate Cahill">
<P>If we had conducted meta-analyses, we would have used the following procedures (and will apply these for future updates, if possible):</P>
<P>Both health-related quality of life and fatigue data would be analysed as continuous variables. We would present results as summary standardized mean differences (SMDs) with 95% confidence intervals (CIs).</P>
<P>For dichotomous data (safety and withdrawals), we would present results as summary risk ratios (RRs) with 95% CIs.</P>
<P>For hemoglobin levels, we have presented results as difference of means (MD) with 95% CIs.<BR/>
</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2013-01-22 16:12:38 -0430" MODIFIED_BY="Kate Cahill">
<P>We would have used the following procedures (and will apply these for future updates, if possible):</P>
<P>We would have noted levels of attrition and explored the impact of high levels of missing data in the overall assessment of treatment effect by using sensitivity analyses.</P>
<P>For all outcomes we would have carried out analysis, as far as possible, on an intention-to-treat basis (i.e. we would have attempted to include all participants randomized to each group in the analyses). If intention-to-treat analysis had not been carried out, then we would have attempted a per-protocol or complete case analysis. The denominator for each outcome in each trial would have been the number randomized minus any participants whose outcomes are known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-01-21 13:58:18 -0430" MODIFIED_BY="Kate Cahill">
<P>We would have used the following procedures (and will apply these for future updates, if possible). We would have used the I<SUP>2 </SUP>statistic to measure statistical heterogeneity between the trials in each analysis. This describes the percentage of total variation across trials that is due to heterogeneity rather than to sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). We would have considered there to be substantial statistical heterogeneity if the I<SUP>2</SUP> was greater than 50% (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and would have explored this by prespecified subgroup analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-01-21 13:59:07 -0430" MODIFIED_BY="Kate Cahill">
<P>We would have used the following procedures (and will apply these for future updates, if possible). When we suspected reporting bias (see &#8216;Selective reporting bias&#8217; above), we would have attempted to contact study authors to obtain missing outcome data. When this was not possible, and if the missing data were thought to introduce serious bias, we would have used sensitivity analyses to explore the impact of including such studies in the overall assessment of results. </P>
<P>We would also have attempted to assess whether the review is subject to publication bias, by using a funnel plot to graphically illustrate variability between trials. If asymmetry were detected, we would have explored causes other than publication bias (e.g. selective outcome reporting, poor methodological quality in smaller studies, true heterogeneity) (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). In future updates we will construct a funnel plot, provided we have 10 or more randomized controlled trials (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-01-21 13:59:47 -0430" MODIFIED_BY="Kate Cahill">
<P>We would have used the procedures previously described (and will apply these for future updates, if possible). We would have carried out statistical analysis using the RevMan 5 software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and summarized the findings using a random-effects model, as differences would have been anticipated in terms of interventions and patients. When I<SUP>2</SUP> is greater than 50%, suggesting substantial heterogeneity, we may decide not to conduct meta-analysis.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-01-21 14:00:12 -0430" MODIFIED_BY="Kate Cahill">
<P>We would have used the following procedures (and will apply these for future updates, if possible). We anticipated clinical heterogeneity for the following participant and intervention characteristics, and therefore we would have carried out the following subgroup analyses:</P>
<OL>
<LI>type of intervention (EPO versus darbepoetin)</LI>
<LI>duration of administration</LI>
<LI>gender</LI>
<LI>erythropoiesis-stimulating agents with and without hematinics</LI>
<LI>year of publication.</LI>
</OL>
<P>We would have restricted subgroup analysis to primary outcomes only (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-01-21 14:01:36 -0430" MODIFIED_BY="Kate Cahill">
<P>We would have used the following procedures (and will apply these for future updates, if possible). If sufficient trials are identified, we plan to conduct a sensitivity analysis comparing the results using all the included trials. We would have compared trials with high methodological quality (studies classified as having a 'low risk of bias') versus those of lower methodological quality (classified as having an 'unclear' or 'high risk of bias') (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We would also have evaluated the risk of attrition bias, as estimated by the percentage of participants lost to follow-up. We would have excluded from the meta-analysis trials with a total attrition of more than 20% or with between-group differences in attrition exceeding 10%, but would still have included them in the review.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the quality of the body of evidence (<LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>). The GRADE approach classifies the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the outcome being assessed (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>; <LINK REF="REF-Guyatt-2011f" TYPE="REFERENCE">Guyatt 2011f</LINK>; <LINK REF="REF-Guyatt-2011g" TYPE="REFERENCE">Guyatt 2011g</LINK>; <LINK REF="REF-Guyatt-2011h" TYPE="REFERENCE">Guyatt 2011h</LINK>).</P>
<P>The <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>, created with GRADE software (<LINK REF="REF-GRADEPro-2008" TYPE="REFERENCE">GRADEPro 2008</LINK>), includes health-related quality of life, fatigue, hemoglobin at the end of the study, adverse events, withdrawals due to adverse events, withdrawals due to lack of efficacy, and withdrawals due to high blood pressure. </P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-21 14:12:18 -0430" MODIFIED_BY="Kate Cahill">
<STUDY_DESCRIPTION MODIFIED="2013-01-21 14:03:28 -0430" MODIFIED_BY="Kate Cahill">
<SEARCH_RESULTS MODIFIED="2013-01-21 14:01:40 -0430" MODIFIED_BY="Kate Cahill">
<P>We identified 337 references using our search strategy (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Three trials with a total of 133 participants met our inclusion criteria (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-01-21 14:03:16 -0430" MODIFIED_BY="Kate Cahill">
<SUBSECTION>
<HEADING LEVEL="4">Interventions and populations assessed in the trials</HEADING>
<P>The three trials reported on EPO compared with placebo (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). Two trials used a subcutaneous route of administration (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>), and one trial administered EPO by an intravenous route (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). The subcutaneous EPO regimen varied from 150 IU/kg-body (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>) to 240 IU/kg-body (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>). The intravenous EPO trial administered the intervention at 50 U/kg, 100 U/kg, and 150 U/kg doses (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). The mean percentage of female participants was 88.17 (± 5.09), with a mean age of 56.43 (± 3.38) years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Location and timing of trials</HEADING>
<P>The trials were published between 1990 and 1997. They were conducted in Sweden (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>), the Netherlands (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>), and the USA (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial methods</HEADING>
<P>All three trials were conducted using a parallel study design. The trials were small with sample sizes ranging from 17 to 70, with a median sample size of 46 and a mean of 44.33 (± SD 26.54), and were conducted without a priori sample size estimation. The follow-ups ranged from eight to 52 weeks. . Two trials were multicenter (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>), and the setting unclear for <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>.</P>
<P>The <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table shows a detailed description of the trials (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-01-21 14:03:28 -0430" MODIFIED_BY="Kate Cahill">
<P>Twenty-one studies were excluded (<LINK REF="STD-Arndt-2005" TYPE="STUDY">Arndt 2005</LINK>; <LINK REF="STD-Birgegard-1991" TYPE="STUDY">Birgegard 1991</LINK>; <LINK REF="STD-Dyjas-2005" TYPE="STUDY">Dyjas 2005</LINK>; <LINK REF="STD-Fantini-1992" TYPE="STUDY">Fantini 1992</LINK>; <LINK REF="STD-Goodnough-1997" TYPE="STUDY">Goodnough 1997</LINK>; <LINK REF="STD-Kaltwasser-2001" TYPE="STUDY">Kaltwasser 2001</LINK>; <LINK REF="STD-Kato-1994" TYPE="STUDY">Kato 1994</LINK>; <LINK REF="STD-Krantz-1995" TYPE="STUDY">Krantz 1995</LINK>; <LINK REF="STD-Matsuda-2001" TYPE="STUDY">Matsuda 2001</LINK>; <LINK REF="STD-Means-1989" TYPE="STUDY">Means 1989</LINK>; <LINK REF="STD-Mercuriali-1996" TYPE="STUDY">Mercuriali 1996</LINK>; <LINK REF="STD-Mercuriali-1997" TYPE="STUDY">Mercuriali 1997</LINK>; <LINK REF="STD-Murphy-1994" TYPE="STUDY">Murphy 1994</LINK>; <LINK REF="STD-Pettersson-1993a" TYPE="STUDY">Pettersson 1993a</LINK>; <LINK REF="STD-Saikawa-1994" TYPE="STUDY">Saikawa 1994</LINK>; <LINK REF="STD-Salvarani-1991" TYPE="STUDY">Salvarani 1991</LINK>; <LINK REF="STD-Swaak-1994" TYPE="STUDY">Swaak 1994</LINK>; <LINK REF="STD-Takashina-1990" TYPE="STUDY">Takashina 1990</LINK>; <LINK REF="STD-Tauchi-1990" TYPE="STUDY">Tauchi 1990</LINK>; <LINK REF="STD-Vreugdenhil-1990" TYPE="STUDY">Vreugdenhil 1990</LINK>; <LINK REF="STD-Vreugdenhil-1992" TYPE="STUDY">Vreugdenhil 1992</LINK>). See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table for reasons for exclusion.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-01-21 14:09:13 -0430" MODIFIED_BY="Kate Cahill">
<P>The risks of bias in the included trials are summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, and are detailed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<ALLOCATION MODIFIED="2012-12-10 14:30:54 -0430" MODIFIED_BY="[Empty name]">
<P>Random Sequence Generation<BR/>The risk of bias arising from the method of generation of the allocation sequence was unclear in all trials (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).<BR/>
<BR/>Allocation Concealment<BR/>The risk of bias arising from the method of allocation concealment was unclear in all trials (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-12-10 14:30:54 -0430" MODIFIED_BY="[Empty name]">
<P>The risk of bias due to blinding of participants and personnel was low in two trials because the drug preparations were covered to make them indistinguishable (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). The risk of bias was unclear in the remaining trial (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>).</P>
<P>The risk of bias arising from lack of blinding of outcome assessment was low in one trial (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>). The risk of bias was unclear in the remaining trials (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>; <LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-12-10 14:30:54 -0430" MODIFIED_BY="[Empty name]">
<P>The risk of attrition bias was low in one trial (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). The risk of attrition bias was high in the remaining trials (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-12-11 16:50:26 -0430" MODIFIED_BY="[Empty name]">
<P>The risk of reporting bias was low in one trial (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>). The risk of reporting bias was high in the remaining trials (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-01-21 14:09:13 -0430" MODIFIED_BY="Kate Cahill">
<P>One study (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>) had high risk of bias for baseline imbalance between comparison groups for gender, duration of disease (years) and medication for treating ARA clinical variables. <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK> did not report baseline characteristics of the patients assigned to the placebo group, and there was no baseline imbalance in <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>. All included trials were suspected to have sponsorship bias, as they were funded by the pharmaceutical company, but we do not have enough information to permit judgment of 'low risk' or 'high risk' for inappropriate influence.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-01-21 14:12:18 -0430" MODIFIED_BY="Kate Cahill">
<P>Results are based on three randomized controlled trials (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> shows evidence on outcomes reported by the trials.</P>
<SUBSECTION>
<HEADING LEVEL="4">Health-related quality of life</HEADING>
<P>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK> reported a significant elevation of energy at the end of the study after week 12 (P = 0.004). Otherwise, Stanford Health Assessment Questionnaire scores, Nottingham Health Profile scores, classification of functional class or joint score index scores did not differ significantly between the comparison groups.</P>
<P>
<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>, reporting patients' global assessment (VAS score 0 to 10), found statistically significant differences comparing the EPO group (median 3.5 and interquartile range 1.0 to 6.0) to placebo (median 4.5 and interquartile range 2.0 to 7.5) at 52 weeks (P = 0.027).</P>
<P>
<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK> assessed patient satisfaction in activities of daily living, using the modified Stanford Health Assessment Questionnaire, and found no significant differences between comparison groups during the trial duration; however, it did not report supporting data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fatigue</HEADING>
<P>This outcome was not assessed by any of the trials included in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety (Adverse events including adverse drug reaction)</HEADING>
<P>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK> found no significant alterations in pulse, blood pressure, platelet counts, albumin, creatinine, alanine aminotransferase, or aspartate aminotransferase values. <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK> found no significant rise in blood pressure and thromboembolic complications. <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK> found no adverse events associated with EPO.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Hemoglobin level at the end of the study</HEADING>
<P>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK> (46 participants) reported a statistically significant increase in hemoglobin level at 12 weeks in the EPO group compared with the placebo group (mean difference (MD) 8.00, 95% confidence interval (CI) 7.43 to 8.57; P = 0.00001) .</P>
<P>
<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK> (70 participants) reported a statistically significant increase in hemoglobin level at 52 weeks in the EPO group (median 134; interquartile range 110 to 158 g/litre) compared with the placebo group (median 112; interquartile range 86 to 128 g/litre; P = 0.001).</P>
<P>
<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK> (17 participants) reported no significant difference between the EPO and placebo groups (MD 4.69, 95% CI -0.17 to 9.55; P = 0.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawals due to adverse events</HEADING>
<P>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK> reported no serious adverse effects causing premature discontinuation. This outcome was not reported by the other two trials (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawals due to lack of efficacy</HEADING>
<P>This outcome was not assessed by the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawals due to high blood pressure</HEADING>
<P>This outcome was not assessed by the trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawals due to high disease activity</HEADING>
<P>
<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>, with eight events in 70 participants, reported no significant difference between the EPO and placebo groups (risk ratio (RR) 0.64, 95% CI 0.16 to 2.46, P = 0.51). The other two trials did not report this outcome (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Withdrawals due to poor compliance</HEADING>
<P>
<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>, with four events in 70 participants, reported no significant difference between the EPO and placebo groups (RR 1.06, 95% CI 0.16 to 7.10, P = 0.95). The other two trials did not report this outcome (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-01-21 14:15:26 -0430" MODIFIED_BY="Kate Cahill">
<SUMMARY_OF_RESULTS MODIFIED="2013-01-21 14:13:08 -0430" MODIFIED_BY="Kate Cahill">
<P>This review of erythropoiesis-stimulating agents for treating anemia in patients with rheumatoid arthritis identified three randomized controlled trials incorporating 133 participants (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). Trials assessed EPO with different follow-ups (eight weeks (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>), 12 weeks (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>) and 52 weeks (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>)) compared with placebo. Two trials administered EPO by a subcutaneous route (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>), and one used an intravenous route (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). The trials were conducted in developed countries (Sweden, the Netherlands, and the USA). Two trials found benefits for health-related quality of life at 12 and 52 weeks (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>). Two trials found benefits in increasing hemoglobin levels at 12 and 52 weeks (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>). All trials had high risks of bias, were underpowered, and were sponsored by the pharmaceutical company. The safety profile of human recombinant erythropoietin is unclear over the course of the trials. See <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> for details.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-01-21 14:13:50 -0430" MODIFIED_BY="Kate Cahill">
<P>This Cochrane review provides inconclusive evidence on the assessed intervention, due both to heterogeneity between trials, and to inadequate information provided by trial reports (<LINK REF="REF-Hopewell-2010" TYPE="REFERENCE">Hopewell 2010</LINK>). During this review, we have identified the following issues, which we feel are particularly relevant to consider as further work is planned. Overall, heterogeneity between trials prevented the pooling of results, with the main areas of variation between trials being differences in outcome definition, and inconsistency of reported outcomes i.e., one trial reported hemoglobin level (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>) and another trial reported hematocrit (<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). It was not advisable to pool data on the health-related quality of life and hemoglobin level at the end of the study, due to inconsistency in reporting the results of these outcomes. It has been suggested that trials should adopt an agreed set of core outcomes for each medical condition (<LINK REF="REF-Clarke-2007" TYPE="REFERENCE">Clarke 2007</LINK>). This approach may reduce the impact of outcome reporting bias (<LINK REF="REF-Kirkham-2010" TYPE="REFERENCE">Kirkham 2010</LINK>). There is an international network initiated in 1992 aimed at improving outcome measurement in rheumatology, named 'Outcome Measures in Rheumatoid Arthritis Clinical Trials' (OMERACT) (<LINK REF="REF-Tugwell-2007" TYPE="REFERENCE">Tugwell 2007</LINK>). A standardized definition of rheumatoid arthritis flare is needed for research and clinical care that combines both clinician and patient perspectives (<LINK REF="REF-Alten-2011" TYPE="REFERENCE">Alten 2011</LINK>; <LINK REF="REF-Bartlett-2012" TYPE="REFERENCE">Bartlett 2012</LINK>; <LINK REF="REF-Bingham-2011" TYPE="REFERENCE">Bingham 2011</LINK>).</P>
<P>Another approach to reduce the impact of outcome reporting bias may be to adopt the recommendations of the Patient-Centered Outcomes Research Institute (PCORI) (<LINK REF="REF-PCORI-2012" TYPE="REFERENCE">PCORI 2012</LINK>). It was established by the United States Congress as an independent, non-profit organization, created to conduct research to provide information about the best available evidence to help patients and their healthcare providers make more informed decisions. PCORI&#8217;s research is intended to give patients a better understanding of the prevention, treatment and care options available, and the science that supports those options (<LINK REF="REF-Basch-2012" TYPE="REFERENCE">Basch 2012</LINK>; <LINK REF="REF-Gabriel-2012" TYPE="REFERENCE">Gabriel 2012</LINK>; <LINK REF="REF-PCORI-2012" TYPE="REFERENCE">PCORI 2012</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-01-21 14:14:57 -0430" MODIFIED_BY="Kate Cahill">
<P>The three randomized controlled trials included in this review all had a high risk of bias. The main source of bias was the lack of detail in describing the generation of randomization sequences or the allocation concealment. The trials also lacked detail about their blinding processes, but two of them described 'similar placebos' (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>). <LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK> was masked to outcome assessment. In this clinical setting, the potential harms of EPO are unknown, due to the lack of detail in presenting safety data. All the trials were underpowered, and were sponsored by the pharmaceutical industry, which reduces confidence in the results. <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK> shows the quality of the evidence supplied by the included trials.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-01-21 14:15:26 -0430" MODIFIED_BY="Kate Cahill">
<P>In the process of conducting a systematic review, there is a group of biases called significance-chasing biases (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). These includes publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. However, we believe that this Cochrane review has a low risk of publication bias, due to the thorough trial search process. Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to study publication bias, in that &#8216;negative&#8217; results remain unpublished (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). This Cochrane review found that two trials had high risk of selective outcome reporting (<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-21 14:17:20 -0430" MODIFIED_BY="Kate Cahill">
<IMPLICATIONS_PRACTICE MODIFIED="2013-01-21 14:16:05 -0430" MODIFIED_BY="Kate Cahill">
<P>We found eligible randomized controlled trials only assessing human recombinant erythropoietin. They provide evidence of benefit in improving health-related quality of life and in increasing hemoglobin levels. The results are based on trials with a high risk of bias, which were sponsored by the pharmaceutical company. The safety profile of human recombinant erythropoietin is unclear in this population. The trial results should therefore be treated with great caution.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-01-21 14:17:20 -0430" MODIFIED_BY="Kate Cahill">
<P>This review highlights a need for well-designed, high-quality randomized trials, with a priori calculations on sample sizes, to assess the benefits and harms of erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. The trials should include outcomes such as quality of life measures, fatigue, adverse events, and hemoglobin level at the end of the study. The trials should be conducted according to 'Outcome Measures in Rheumatoid Arthritis Clinical Trials' (OMERACT) recommendations for rheumatoid arthritis (<LINK REF="REF-Alten-2011" TYPE="REFERENCE">Alten 2011</LINK>; <LINK REF="REF-Bartlett-2012" TYPE="REFERENCE">Bartlett 2012</LINK>; <LINK REF="REF-Bingham-2011" TYPE="REFERENCE">Bingham 2011</LINK>; <LINK REF="REF-Tugwell-2007" TYPE="REFERENCE">Tugwell 2007</LINK>) and the Patient-Centered Outcomes Research Institute (PCORI) recommendations (<LINK REF="REF-Basch-2012" TYPE="REFERENCE">Basch 2012</LINK>; <LINK REF="REF-Gabriel-2012" TYPE="REFERENCE">Gabriel 2012</LINK>; <LINK REF="REF-PCORI-2012" TYPE="REFERENCE">PCORI 2012</LINK>).</P>
<P>Rheumatoid arthritis is a chronic inflammatory state characterized by high circulating levels of interleukin-6, which is the main factor causing anemia in this population; patients suffering from this disorder should therefore be treated with disease-modifying antirheumatic drugs (DMARDs), but EPO could still be an issue in countries where DMARDs are not yet accessible. Potential trials for assessing benefits and harms of erythropoiesis-stimulating agents to treat anemia in rheumatoid arthritis should be reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement for improving the quality of reporting of efficacy and of harms in clinical research (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>; <LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-12-12 11:42:44 -0430" MODIFIED_BY="[Empty name]">
<P>We want to express our gratitude to Elizabeth Ghogomu, Jordi Pardo, the peer-reviewers and Editor for their comments and suggestions which improved the quality of this Cochrane review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-01-21 14:17:41 -0430" MODIFIED_BY="[Empty name]">
<P>In 2004 Arturo Martí-Carvajal was employed by Eli Lilly to run a four-hour workshop on 'How to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>In 2007 Arturo Martí-Carvajal was employed by Merck to run a four-hour workshop 'How to critically appraise clinical trials and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>Ivan Solà, Luís Agreda-Pérez and Daniel Simancas: none known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-01-21 14:17:30 -0430" MODIFIED_BY="[Empty name]">
<P>Conceiving the review (guarantor): Arturo Martí-Carvajal (AMC)</P>
<P>Screening search results: AMC, Luís Agreda-Pérez (LAP), Daniel Simancas (DS)</P>
<P>Screening retrieved papers against inclusion criteria: AMC</P>
<P>Appraising quality of papers: AMC, LAP, DS</P>
<P>Abstracting data from papers: AMC, LAP, Ivan Solà (IS).</P>
<P>Data management for the review: AMC, LAP</P>
<P>Entering data into RevMan 5.1: AMC, IS</P>
<P>Double entry of data: AMC, DS, IS.</P>
<P>Interpretation of data: AMC, IS, LAP, DS.</P>
<P>Statistical analysis: AMC, IS</P>
<P>Writing the review: AMC</P>
<P>Comment and editing of review drafts: AMC, IS, LAP, DS.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-01-21 14:17:55 -0430" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>1. Assessment of risk of bias of the included RCTs was adapted to the new Cochrane methodology recommendations.<BR/>2. We amended the terminology for number of withdrawals due to lack of efficacy, number of withdrawals due to high blood pressure, and number of withdrawals due to adverse events by withdrawals due to lack of efficacy, withdrawals due to high blood pressure, and withdrawals due to high disease activity. This was because these outcomes are binary.<BR/>3. We included withdrawals due to high disease activity and withdrawals due to poor compliance.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-22 13:11:51 -0430" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-21 14:35:06 -0430" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-01-18 09:32:20 -0430" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Nordstr_x00f6_m-1997" MODIFIED="2012-12-10 14:30:54 -0430" MODIFIED_BY="[Empty name]" NAME="Nordström 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-12-10 14:30:01 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nordström D, Lindroth Y, Marsal L, Hafstrom I, Henrich C, Rantapaa-Dahlqvist S et al</AU>
<TI>Availability of iron and degree of inflammation modifies the response to recombinant human erythropoietin when treating anemia of chronic disease in patients with rheumatoid arthritis</TI>
<SO>Rheumatology International</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>2</NO>
<PG>67-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9266623"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peeters-1996" MODIFIED="2013-01-18 09:32:20 -0430" MODIFIED_BY="[Empty name]" NAME="Peeters 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-04-04 09:01:01 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peeters HR, Jongen-Lavrencic M, Bakker CH, Vreugdenhil G, Breedveld FC, Swaak AJ</AU>
<TI>Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures</TI>
<SO>Rheumatology International</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>5-6</NO>
<PG>201-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="10399796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-18 09:32:20 -0430" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, Swaak AJ</AU>
<TI>Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomized placebo controlled double blind 52 weeks clinical trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>10</NO>
<PG>739-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="8984939"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pincus-1990" MODIFIED="2011-04-04 09:02:49 -0430" MODIFIED_BY="[Empty name]" NAME="Pincus 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-04-04 09:02:49 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pincus T, Olsen NJ, Russell IJ, Wolfe F, Harris ER, Schnitzer TJ, et al</AU>
<TI>Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis</TI>
<SO>The American Journal of Medicine</SO>
<YR>1990</YR>
<VL>89</VL>
<NO>2</NO>
<PG>161-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="2200263"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-01-21 14:35:06 -0430" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arndt-2005" MODIFIED="2011-04-04 09:03:05 -0430" MODIFIED_BY="[Empty name]" NAME="Arndt 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-04-04 09:03:05 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B</AU>
<TI>Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin</TI>
<SO>Annals of Hematology</SO>
<YR>2005</YR>
<VL>84</VL>
<NO>3</NO>
<PG>159-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="15565327"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Birgegard-1991" MODIFIED="2011-04-04 09:03:13 -0430" MODIFIED_BY="[Empty name]" NAME="Birgegard 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-04-04 09:03:13 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Birgegard G, Gudbjronsson B, Hallgren R, Wide L</AU>
<TI>Anemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin</TI>
<SO>Contributions to Nephrology</SO>
<YR>1991</YR>
<VL>88</VL>
<PG>295-303; discussion 304-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="2040192"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyjas-2005" MODIFIED="2011-03-31 16:54:01 -0430" MODIFIED_BY="[Empty name]" NAME="Dyjas 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-03-31 16:54:01 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyjas R, Bulanowski M, Ficek R, Witkowicz J, Chudek J, Wiecek A</AU>
<TI>[Influence of recombinant human erythropoietin (rHuEPO) on plasma levels of selected hormones in females with rheumatoid arthritis]</TI>
<TO>Wplyw leczenia niedokrwistosci za pomoca ludzkiej erytropoetyny uzyskanej metodt rekombinacji genetycznej (rHuEPO) na stezenie w osoczu wybranych hormonow u kobiet chorych na reumatoidalne zapalenie stawow.</TO>
<SO>Polskie Archiwum Medycyny Wewnetrznej</SO>
<YR>2005</YR>
<VL>114</VL>
<NO>2</NO>
<PG>731-7</PG>
<IDENTIFIERS MODIFIED="2011-03-31 16:53:59 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="16808310"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fantini-1992" MODIFIED="2011-04-01 22:21:31 -0430" MODIFIED_BY="[Empty name]" NAME="Fantini 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-04-01 22:21:31 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fantini F, Gattinara M, Gerloni V, Bergomi P, Cirla E</AU>
<TI>Severe anemia associated with active systemic-onset juvenile rheumatoid arthritis successfully treated with recombinant human erythropoietin: a pilot study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1992</YR>
<VL>35</VL>
<NO>6</NO>
<PG>724-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="1599527"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodnough-1997" MODIFIED="2011-04-04 09:03:57 -0430" MODIFIED_BY="[Empty name]" NAME="Goodnough 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-04-04 09:03:57 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodnough LT, Marcus RE</AU>
<TI>The erythropoietic response to erythropoietin in patients with rheumatoid arthritis</TI>
<SO>The Journal of Laboratory and Clinical Medicine</SO>
<YR>1997</YR>
<VL>130</VL>
<NO>4</NO>
<PG>381-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9358076"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaltwasser-2001" MODIFIED="2011-04-04 09:04:09 -0430" MODIFIED_BY="[Empty name]" NAME="Kaltwasser 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-04 09:04:09 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B</AU>
<TI>Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>11</NO>
<PG>2430-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11708414"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kato-1994" MODIFIED="2011-04-04 09:04:17 -0430" MODIFIED_BY="[Empty name]" NAME="Kato 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-04-04 09:04:17 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kato Y, Takagi C, Tanaka J, Masaki Y, Furuya H</AU>
<TI>Effect of daily subcutaneous administration of recombinant erythropoietin on chronic anemia in rheumatoid arthritis</TI>
<SO>Internal Medicine (Tokyo, Japan)</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>4</NO>
<PG>193-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="8069012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krantz-1995" MODIFIED="2011-01-26 09:58:18 -0430" MODIFIED_BY="[Empty name]" NAME="Krantz 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-01-26 09:58:18 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krantz SB</AU>
<TI>Erythropoietin and the anaemia of chronic disease</TI>
<SO>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</SO>
<YR>1995</YR>
<VL>10 Suppl 2</VL>
<PG>10-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="7644100"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsuda-2001" MODIFIED="2011-04-01 22:49:25 -0430" MODIFIED_BY="[Empty name]" NAME="Matsuda 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-04-01 22:49:25 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsuda S, Kondo M, Mashima T, Hoshino S, Shinohara N, Sumida S</AU>
<TI>Recombinant human erythropoietin therapy for autologous blood donation in rheumatoid arthritis patients undergoing total hip or knee arthroplasty</TI>
<SO>Orthopedics</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>1</NO>
<PG>41-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="11199350"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Means-1989" MODIFIED="2011-04-04 09:04:46 -0430" MODIFIED_BY="[Empty name]" NAME="Means 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-04-04 09:04:46 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Means RT Jr, Olsen NJ, Krantz SB, Dessypris EN, Graber SE, Stone WJ, et al</AU>
<TI>Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1989</YR>
<VL>32</VL>
<NO>5</NO>
<PG>638-42</PG>
<IDENTIFIERS MODIFIED="2011-03-31 17:14:01 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="2719734"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercuriali-1996" MODIFIED="2011-04-04 09:04:56 -0430" MODIFIED_BY="[Empty name]" NAME="Mercuriali 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-04-04 09:04:56 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mercuriali F</AU>
<TI>Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia</TI>
<SO>Seminars in Hematology</SO>
<YR>1996</YR>
<VL>33</VL>
<NO>2 Suppl 2</NO>
<PG>18-20; discussion 21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="8723576"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mercuriali-1997" MODIFIED="2013-01-21 14:34:02 -0430" MODIFIED_BY="[Empty name]" NAME="Mercuriali 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-01-21 14:34:02 -0430" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mercuriali F, Inghilleri G, Biffi E, Colotti MT, Vinci A, Sinigaglia L, et al</AU>
<TI>Comparison between intravenous and subcutaneous recombinant human erythropoietin (Epoetin alfa) administration in presurgical autologous blood donation in anemic rheumatoid arthritis patients undergoing major orthopedic surgery</TI>
<SO>Vox Sanguinis</SO>
<YR>1997</YR>
<VL>72</VL>
<NO>2</NO>
<PG>93-100</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="9088076"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-18 09:41:21 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mercuriali F; Gualtieri G; Biffi E; Inghilleri G; Colotti M; Vinci A, et al</AU>
<TI>Intravenous vs subcutaneous erythropoietin for autologous blood donation in anemic rheumatoid arthritis patients</TI>
<SO>Transfusion Supplement</SO>
<YR>1994</YR>
<VL>34</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-18 09:41:47 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Mercuriali F; Gualtieri G; Inghilleri G; Biffi E; Vinci A; Colotti M, et al</AU>
<TI>Erythropoietin and autologous blood donation in surgical rheumatoid arthritis patients with anemia</TI>
<SO>Transfusion Abstract</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>28</NO>
<CY>Florida</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1994" MODIFIED="2013-01-21 14:35:06 -0430" MODIFIED_BY="[Empty name]" NAME="Murphy 1994" YEAR="1994">
<REFERENCE MODIFIED="2013-01-21 14:35:06 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy EA, Bell AL, Wojtulewski J, Brzeski M, Madhok R, Capell HA</AU>
<TI>Study of erythropoietin in treatment of anaemia in patients with rheumatoid arthritis</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6965</NO>
<PG>1337-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="7866082"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettersson-1993a" MODIFIED="2011-12-05 15:22:12 -0430" MODIFIED_BY="[Empty name]" NAME="Pettersson 1993a" YEAR="1993">
<REFERENCE MODIFIED="2011-12-05 15:22:12 -0430" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pettersson T&lt;br&gt;Rosenlof K&lt;br&gt;Friman C&lt;br&gt;Mickos A&lt;br&gt;Teppo AM&lt;br&gt;Fyhrquist F&lt;/p&gt;" NOTES_MODIFIED="2011-12-05 15:22:12 -0430" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pettersson T, Rosenlof K, Friman C, Mickos A, Teppo A M, Fyhrquist F</AU>
<TI>Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>4</NO>
<PG>188-93</PG>
<IDENTIFIERS MODIFIED="2011-12-05 15:22:12 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-05 15:22:12 -0430" MODIFIED_BY="[Empty name]" TYPE="MEDLINE" VALUE=" 8356412"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saikawa-1994" MODIFIED="2011-04-04 09:05:34 -0430" MODIFIED_BY="[Empty name]" NAME="Saikawa 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-04-04 09:05:34 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saikawa I, Hotokebuchi T, Arita C, Inaba S, Shuto T, Tsutsui H, et al</AU>
<TI>Autologous blood transfusion with recombinant erythropoietin treatment. 22 arthroplasties for rheumatoid arthritis</TI>
<SO>Acta Orthopaedica Scandinavica</SO>
<YR>1994</YR>
<VL>65</VL>
<NO>1</NO>
<PG>15-9</PG>
<IDENTIFIERS MODIFIED="2011-03-31 17:40:29 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="8154276"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salvarani-1991" MODIFIED="2013-01-18 09:45:12 -0430" MODIFIED_BY="[Empty name]" NAME="Salvarani 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-01-18 09:45:12 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salvarani C, Lasagni D, Casali B, Macchioni P, Boiardi L, Rossi F, et al</AU>
<TI>Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1991</YR>
<VL>18</VL>
<NO>8</NO>
<PG>1168-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="1941817"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swaak-1994" MODIFIED="2011-04-04 09:06:02 -0430" MODIFIED_BY="[Empty name]" NAME="Swaak 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-04-04 09:06:02 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Swaak AJ, Nieuwenhuizen C, Vreugdenhil G</AU>
<TI>Recombinant human erythropoietin (r-hu-EPO) treatment in patients with rheumatoid arthritis and anaemia of chronic disease (ACD)</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>1994</YR>
<VL>12</VL>
<NO>5</NO>
<PG>577</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="7842542"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takashina-1990" MODIFIED="2011-04-04 09:06:10 -0430" MODIFIED_BY="[Empty name]" NAME="Takashina 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-04-04 09:06:10 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takashina N, Kondo H, Kashiwazaki S</AU>
<TI>Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1990</YR>
<VL>17</VL>
<NO>7</NO>
<PG>885-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="2213753"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tauchi-1990" MODIFIED="2011-04-04 09:06:24 -0430" MODIFIED_BY="[Empty name]" NAME="Tauchi 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-04-04 09:06:24 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tauchi T, Ohyashiki JH, Fujieda H, Lin KY, Ohyashiki K, Toyama K</AU>
<TI>Correction of anaemia in rheumatoid arthritis by recombinant human erythropoietin</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1990</YR>
<VL>29</VL>
<NO>3</NO>
<PG>235-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="2357513"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vreugdenhil-1990" MODIFIED="2011-03-31 17:04:22 -0430" MODIFIED_BY="[Empty name]" NAME="Vreugdenhil 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-03-31 17:04:22 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vreugdenhil G, Swaak AJ</AU>
<TI>The role of erythropoietin in the anaemia of chronic disease in rheumatoid arthritis</TI>
<SO>Clinical Rheumatology</SO>
<YR>1990</YR>
<VL>9</VL>
<NO>1</NO>
<PG>22-7</PG>
<IDENTIFIERS MODIFIED="2011-03-31 17:03:44 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="2185909"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vreugdenhil-1992" MODIFIED="2011-04-04 09:06:41 -0430" MODIFIED_BY="[Empty name]" NAME="Vreugdenhil 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-04-04 09:06:41 -0430" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vreugdenhil G, Manger B, Nieuwenhuizen C, Feelders RA, van Eijk HG, Swaak AJ</AU>
<TI>Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis</TI>
<SO>Annals of Hematology</SO>
<YR>1992</YR>
<VL>65</VL>
<NO>6</NO>
<PG>265-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="1457588"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2011-04-01 22:56:28 -0430" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-01-22 13:11:51 -0430" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-01-22 13:11:51 -0430" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Agarwal-2009" MODIFIED="2010-01-25 23:21:45 -0430" MODIFIED_BY="[Empty name]" NAME="Agarwal 2009" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal N, Prchal JT</AU>
<TI>Anemia of chronic disease (anemia of inflammation)</TI>
<SO>Acta Haematologica</SO>
<YR>2009</YR>
<VL>122</VL>
<PG>103-8</PG>
<IDENTIFIERS MODIFIED="2010-01-25 23:21:45 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 23:21:45 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19907147"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Al_x002d_Ghamdi-2009" MODIFIED="2010-01-23 09:16:31 -0430" MODIFIED_BY="[Empty name]" NAME="Al-Ghamdi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Al-Ghamdi A, Attar SM</AU>
<TI>Extra-articular manifestations of rheumatoid arthritis: a hospital-based study</TI>
<SO>Annals of Saudí Medicine</SO>
<YR>2009</YR>
<VL>29</VL>
<PG>189-93</PG>
<IDENTIFIERS MODIFIED="2010-01-23 09:16:31 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-23 09:16:31 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19448378"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Alten-2011" MODIFIED="2013-01-18 09:51:04 -0430" MODIFIED_BY="[Empty name]" NAME="Alten 2011" TYPE="OTHER">
<AU>Alten R, Pohl C, Choy EH, Christensen R, Furst DE, Hewlett SE, et al</AU>
<TI>Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>8</NO>
<PG>1745-50</PG>
<IDENTIFIERS MODIFIED="2012-07-26 13:41:54 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21807796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andrews-2007" MODIFIED="2010-01-29 12:19:58 -0430" MODIFIED_BY="[Empty name]" NAME="Andrews 2007" TYPE="JOURNAL_ARTICLE">
<AU>Andrews NC, Schmidt PJ</AU>
<TI>Iron homeostasis</TI>
<SO>Annual Review of Physiology</SO>
<YR>2007</YR>
<VL>69</VL>
<PG>69-85</PG>
<IDENTIFIERS MODIFIED="2010-01-29 12:19:48 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 12:19:48 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17014365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andrews-2008" MODIFIED="2010-01-25 21:57:54 -0430" MODIFIED_BY="[Empty name]" NAME="Andrews 2008" TYPE="JOURNAL_ARTICLE">
<AU>Andrews NC</AU>
<TI>Forging a field: the golden age of iron biology</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>112</VL>
<PG>219-30</PG>
<IDENTIFIERS MODIFIED="2010-01-25 21:57:54 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 21:57:54 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18606887"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arnett-1988" MODIFIED="2013-01-18 09:51:58 -0430" MODIFIED_BY="[Empty name]" NAME="Arnett 1988" TYPE="JOURNAL_ARTICLE">
<AU>Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al</AU>
<TI>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>315-24</PG>
<IDENTIFIERS MODIFIED="2010-01-20 14:43:35 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-20 14:43:35 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3358796"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baer-1997" MODIFIED="2012-01-24 12:56:50 -0430" MODIFIED_BY="[Empty name]" NAME="Baer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Baer AN, Dessypris EN, Goldwasser E, Krantz SB</AU>
<TI>Blunted erythropoietin response to anaemia in rheumatoid arthritis</TI>
<SO>British Journal of Haematology</SO>
<YR>1987</YR>
<VL>66</VL>
<PG>599-64</PG>
<IDENTIFIERS MODIFIED="2012-01-24 12:56:50 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-24 12:56:50 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 3663512"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2013-01-22 13:07:54 -0430" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:38:23 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:38:23 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21208779"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bartlett-2012" MODIFIED="2013-01-22 13:08:06 -0430" MODIFIED_BY="[Empty name]" NAME="Bartlett 2012" TYPE="OTHER">
<AU>Bartlett SJ, Hewlett S, Bingham CO 3rd, Woodworth TG, Alten R, Pohl C, et al</AU>
<TI>Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>Jul 6. [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2012-07-26 13:39:10 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22772326"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Basch-2012" MODIFIED="2012-10-16 10:24:57 -0430" MODIFIED_BY="[Empty name]" NAME="Basch 2012" TYPE="JOURNAL_ARTICLE">
<AU>Basch E, Aronson N, Berg A, Flum D, Gabriel S, Goodman SN, et al</AU>
<TI>Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>307</VL>
<NO>15</NO>
<PG>1636-40</PG>
<IDENTIFIERS MODIFIED="2012-07-27 06:11:38 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22511692"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bennet-2008" MODIFIED="2013-01-18 09:54:29 -0430" MODIFIED_BY="[Empty name]" NAME="Bennet 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al</AU>
<TI>Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia</TI>
<SO>JAMA</SO>
<YR>2008</YR>
<VL>299</VL>
<PG>914-24</PG>
<IDENTIFIERS MODIFIED="2010-01-29 14:53:10 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 14:53:10 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18314434 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bingham-2011" MODIFIED="2013-01-22 13:08:24 -0430" MODIFIED_BY="[Empty name]" NAME="Bingham 2011" TYPE="OTHER">
<AU>Bingham CO 3rd, Alten R, Bartlett SJ, Bykerk VP, Brooks PM, Choy E, et al</AU>
<TI>Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2011</YR>
<VL>38</VL>
<NO>8</NO>
<PG>1751-8</PG>
<IDENTIFIERS MODIFIED="2012-07-26 13:40:18 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="21807797"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blumenauer-2002" MODIFIED="2013-01-21 14:35:23 -0430" MODIFIED_BY="[Empty name]" NAME="Blumenauer 2002" TYPE="COCHRANE_REVIEW">
<AU>Blumenauer BBTB, Judd M, Wells GA, Burls A, Cranney A, Hochberg MC, et al</AU>
<TI>Infliximab for the treatment of rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:30:22 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:30:22 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blumenauer-2003" MODIFIED="2012-12-18 16:22:09 -0430" MODIFIED_BY="[Empty name]" NAME="Blumenauer 2003" TYPE="COCHRANE_REVIEW">
<AU>Blumenauer BBTB, Cranney A, Burls A, Coyle D, Hochberg MC, Tugwell P, Wells GA</AU>
<TI>Etanercept for the treatment of rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:22:09 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:22:09 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004525"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Capocasale-2008" MODIFIED="2013-01-21 14:35:35 -0430" MODIFIED_BY="[Empty name]" NAME="Capocasale 2008" TYPE="JOURNAL_ARTICLE">
<AU>Capocasale RJ, Makropoulos DA, Achuthanandam R, Stowell N, Quinn J, Rafferty PA, et al</AU>
<TI>Myelodysplasia and anemia of chronic disease in human tumor necrosis factor-alpha transgenic mice</TI>
<SO>Cytometry A</SO>
<YR>2008</YR>
<VL>73</VL>
<PG>148-59</PG>
<IDENTIFIERS MODIFIED="2012-01-24 12:59:21 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-24 12:59:21 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18205195"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cartwright-1966" MODIFIED="2010-01-25 22:55:06 -0430" MODIFIED_BY="[Empty name]" NAME="Cartwright 1966" TYPE="JOURNAL_ARTICLE">
<AU>Cartwright GE</AU>
<TI>The anemia of chronic disorders</TI>
<SO>Seminars in Hematology</SO>
<YR>1966</YR>
<VL>3</VL>
<PG>351-75</PG>
<IDENTIFIERS MODIFIED="2010-01-25 22:54:58 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 22:54:58 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="5341723"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cases-2003" MODIFIED="2010-01-29 16:29:42 -0430" MODIFIED_BY="[Empty name]" NAME="Cases 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cases A</AU>
<TI>Darbepoetin alfa: a novel erythropoiesis-stimulating protein</TI>
<SO>Drugs of Today (Barc)</SO>
<YR>2003</YR>
<VL>39</VL>
<PG>477-95</PG>
<IDENTIFIERS MODIFIED="2010-01-29 16:29:42 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 16:29:42 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12973399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2007" MODIFIED="2012-01-23 14:40:50 -0430" MODIFIED_BY="[Empty name]" NAME="Clarke 2007" TYPE="JOURNAL_ARTICLE">
<AU>Clarke M</AU>
<TI>Standardising outcomes for clinical trials and systematic reviews</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>39</PG>
<IDENTIFIERS MODIFIED="2012-01-23 14:40:15 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-23 14:40:15 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18039365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Coussons-2005" MODIFIED="2010-01-29 14:15:38 -0430" MODIFIED_BY="[Empty name]" NAME="Coussons 2005" TYPE="JOURNAL_ARTICLE">
<AU>Coussons PJ, Baig S, Fanutti C, Grant R</AU>
<TI>Novel tissue remodelling roles for human recombinant erythropoietin</TI>
<SO>Biochemical Society Transactions</SO>
<YR>2005</YR>
<VL>33 (Pt 5)</VL>
<PG>1129-30</PG>
<IDENTIFIERS MODIFIED="2010-01-29 14:15:16 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 14:15:16 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16246063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cronstein-2007" MODIFIED="2010-01-25 20:42:44 -0430" MODIFIED_BY="[Empty name]" NAME="Cronstein 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cronstein BN</AU>
<TI>Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis</TI>
<SO>Bulletin of the NYU Hospital for Joint Diseases</SO>
<YR>2007</YR>
<VL>65 (Suppl 1)</VL>
<PG>11-5</PG>
<IDENTIFIERS MODIFIED="2010-01-25 20:42:44 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 20:42:44 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17708739 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dayer-2010" MODIFIED="2010-01-25 20:33:34 -0430" MODIFIED_BY="[Empty name]" NAME="Dayer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dayer JM, Choy E</AU>
<TI>Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2010</YR>
<VL>49</VL>
<PG>15-24</PG>
<IDENTIFIERS MODIFIED="2010-01-25 20:33:34 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 20:33:34 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19854855"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Demirag-2009" MODIFIED="2013-01-22 13:08:49 -0430" MODIFIED_BY="[Empty name]" NAME="Demirag 2009" TYPE="JOURNAL_ARTICLE">
<AU>Demirag MD, Haznedaroglu S, Sancak B, Konca C, Gulbahar O, Ozturk MA, et al</AU>
<TI>Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis</TI>
<SO>Internal Medicine</SO>
<YR>2009</YR>
<VL>48</VL>
<PG>421-6</PG>
<IDENTIFIERS MODIFIED="2010-01-25 21:45:45 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 21:45:45 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19293540"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2008a" MODIFIED="2010-01-29 16:45:26 -0430" MODIFIED_BY="[Empty name]" NAME="FDA 2008a" TYPE="OTHER">
<AU>Food and Drug Administration</AU>
<TI>EPOGEN (epoetin alfa) solution</TI>
<SO>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9169 [Accessed January 29, 2010]</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2008b" MODIFIED="2010-01-29 16:46:33 -0430" MODIFIED_BY="[Empty name]" NAME="FDA 2008b" TYPE="OTHER">
<AU>Food and Drug Administration</AU>
<TI>Erythropoiesis Stimulating Agents: Aranesp (darbepoetin alfa), Epogen (epoetin alfa), and Procrit (epoetin alfa)</TI>
<SO>http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110251.htm</SO>
<YR>March 07, 2008 (Accessed Jan 29, 2010)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fonseca-2009" MODIFIED="2010-01-25 20:47:38 -0430" MODIFIED_BY="[Empty name]" NAME="Fonseca 2009" TYPE="JOURNAL_ARTICLE">
<AU>Fonseca JE, Santos MJ, Canhão H, Choy E</AU>
<TI>Interleukin-6 as a key player in systemic inflammation and joint destruction</TI>
<SO>Autoimmunity Reviews</SO>
<YR>2009</YR>
<VL>8</VL>
<PG>538-42</PG>
<IDENTIFIERS MODIFIED="2010-01-25 20:47:27 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 20:47:27 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19189867"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Furst-2009" MODIFIED="2013-01-22 13:09:02 -0430" MODIFIED_BY="[Empty name]" NAME="Furst 2009" TYPE="JOURNAL_ARTICLE">
<AU>Furst DE, Chang H, Greenberg JD, Ranganath VK, Reed G, Ozturk ZE, et al</AU>
<TI>Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2009</YR>
<VL>27</VL>
<PG>560-6</PG>
<IDENTIFIERS MODIFIED="2010-01-22 14:40:47 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 14:40:47 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19772785"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gabriel-2012" MODIFIED="2013-01-21 14:35:56 -0430" MODIFIED_BY="[Empty name]" NAME="Gabriel 2012" TYPE="OTHER">
<AU>Gabriel SE, Normand SL</AU>
<TI>Getting the methods right - the foundation of patient-centered outcomes research</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2012 Jul 25 [Epub ahead of print]</YR>
<IDENTIFIERS MODIFIED="2012-07-27 06:11:38 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22830434"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ganz-2009" MODIFIED="2010-01-25 20:55:25 -0430" MODIFIED_BY="[Empty name]" NAME="Ganz 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ganz T, Nemeth E</AU>
<TI>Iron sequestration and anemia of inflammation</TI>
<SO>Seminars in Hematology</SO>
<YR>2009</YR>
<VL>46</VL>
<PG>387-93</PG>
<IDENTIFIERS MODIFIED="2010-01-25 20:55:25 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 20:55:25 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19786207"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glaspy-2009" MODIFIED="2010-01-29 12:47:09 -0430" MODIFIED_BY="[Empty name]" NAME="Glaspy 2009" TYPE="JOURNAL_ARTICLE">
<AU>Glaspy 2009</AU>
<TI>Erythropoietin in cancer patients</TI>
<SO>Annual Review of Medicine</SO>
<YR>2009</YR>
<VL>60</VL>
<PG>181-92</PG>
<IDENTIFIERS MODIFIED="2010-01-29 12:47:09 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 12:47:09 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18980468"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-GRADEPro-2008" MODIFIED="2012-09-14 10:02:52 -0430" MODIFIED_BY="[Empty name]" NAME="GRADEPro 2008" TYPE="COMPUTER_PROGRAM">
<AU>Brozek J, Oxman A, Schünemann H</AU>
<TI>GRADEpro</TI>
<YR>2008</YR>
<EN>3.2 for Windows</EN>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grassi-1998" MODIFIED="2010-01-22 13:28:45 -0430" MODIFIED_BY="[Empty name]" NAME="Grassi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Grassi W, De Angelis R, Lamanna G, Cervini C</AU>
<TI>The clinical features of rheumatoid arthritis</TI>
<SO>European Journal of Radiology</SO>
<YR>1998</YR>
<VL>27 (Suppl 1)</VL>
<PG>18-24</PG>
<IDENTIFIERS MODIFIED="2010-01-22 13:28:45 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 13:28:45 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9652497"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gudbj_x00f6_rnsson-1992" MODIFIED="2010-02-01 16:08:35 -0430" MODIFIED_BY="[Empty name]" NAME="Gudbjörnsson 1992" TYPE="JOURNAL_ARTICLE">
<AU>Gudbjörnsson B, Hällgren R, Wide L, Birgegård G</AU>
<TI>Response of anaemia in rheumatoid arthritis to treatment with subcutaneous recombinant human erythropoietin</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>1992</YR>
<VL>51</VL>
<PG>747-52</PG>
<IDENTIFIERS MODIFIED="2010-02-01 16:08:35 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-01 16:08:35 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1616357"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2013-01-18 10:13:01 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:21:31 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:21:31 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21195583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2013-01-22 13:09:17 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al</AU>
<TI>GRADE guidelines: 2. Framing the question and deciding on important outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:22:47 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:22:47 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21194891"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2013-01-22 13:09:26 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:40:17 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:40:17 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21247734"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2013-01-22 13:09:38 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence--publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:09:09 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:09:09 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21802904"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2013-01-18 10:17:33 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence--imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:11:46 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:11:46 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21839614"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011f" MODIFIED="2013-01-22 13:09:49 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011f" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence--inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:12:59 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:12:59 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21803546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011g" MODIFIED="2013-01-18 10:18:00 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011g" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence--indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:15:23 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:15:23 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21802903"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011h" MODIFIED="2013-01-22 13:10:00 -0430" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011h" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:17:43 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:17:43 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21802902"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Han-2007" MODIFIED="2013-01-22 13:10:12 -0430" MODIFIED_BY="[Empty name]" NAME="Han 2007" TYPE="JOURNAL_ARTICLE">
<AU>Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, et al</AU>
<TI>Association of anemia and physical disability among patients with rheumatoid arthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2007</YR>
<VL>34</VL>
<PG>2177-82</PG>
<IDENTIFIERS MODIFIED="2010-01-23 09:08:03 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-23 09:08:03 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17937474"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hershman-2009" MODIFIED="2010-01-29 15:46:10 -0430" MODIFIED_BY="[Empty name]" NAME="Hershman 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI</AU>
<TI>Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2009</YR>
<VL>101</VL>
<PG>1633-41</PG>
<IDENTIFIERS MODIFIED="2010-01-29 15:45:32 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 15:45:32 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19903808 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-01-20 16:45:15 -0430" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2010-01-20 16:44:42 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-20 16:44:42 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-12-07 09:40:38 -0430" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.5 [updated September 29th, 2009]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-1988" MODIFIED="2012-03-02 13:40:46 -0430" MODIFIED_BY="[Empty name]" NAME="Hochberg 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Arnold CM, Hogans BB, Spivak JL</AU>
<TI>Serum immunoreactive erythropoietin in rheumatoid arthritis: impaired response to anemia</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>1318-21</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:40:46 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:40:46 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3178910"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hochberg-2008" MODIFIED="2010-01-22 14:59:12 -0430" MODIFIED_BY="[Empty name]" NAME="Hochberg 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hochberg MC, Johnston SS, John AK</AU>
<TI>The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>2008</YR>
<VL>24</VL>
<PG>469-80</PG>
<IDENTIFIERS MODIFIED="2010-01-22 14:59:12 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 14:59:12 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18179735 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hopewell-2010" MODIFIED="2013-01-21 14:36:13 -0430" MODIFIED_BY="[Empty name]" NAME="Hopewell 2010" TYPE="OTHER">
<AU>Hopewell S, Clarke M, Higgins JPT (editors)</AU>
<TI>Core reporting of outcomes in effectiveness trials</TI>
<SO>Cochrane Methods. Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<VL>Suppl 1</VL>
<PG>1-29</PG>
<IDENTIFIERS MODIFIED="2012-01-23 14:08:57 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-23 14:08:57 -0430" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISSN 2044-4702"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ibbotson--2001" MODIFIED="2010-01-29 16:33:48 -0430" MODIFIED_BY="[Empty name]" NAME="Ibbotson  2001" TYPE="JOURNAL_ARTICLE">
<AU>Ibbotson T, Goa KL</AU>
<TI>Darbepoetin alfa</TI>
<SO>Drugs</SO>
<YR>2001</YR>
<VL>61</VL>
<PG>2097-104</PG>
<IDENTIFIERS MODIFIED="2010-01-29 16:33:48 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 16:33:48 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11735636"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Imboden-2009" MODIFIED="2010-01-29 12:13:12 -0430" MODIFIED_BY="[Empty name]" NAME="Imboden 2009" TYPE="JOURNAL_ARTICLE">
<AU>Imboden JB</AU>
<TI>The immunopathogenesis of rheumatoid arthritis</TI>
<SO>Annual Review of Pathology</SO>
<YR>2009</YR>
<VL>4</VL>
<PG>417&#8211;34</PG>
<IDENTIFIERS MODIFIED="2010-01-29 12:12:52 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 12:12:52 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18954286"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2013-01-22 13:10:36 -0430" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<NO>10</NO>
<PG>781-8</PG>
<IDENTIFIERS MODIFIED="2012-01-24 13:08:28 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-24 13:08:28 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15545678"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2012-01-23 13:42:37 -0430" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>The art of getting it wrong</TI>
<SO>Research Synthesis Methods</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>3-4</NO>
<PG>169-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jaworski-2008" MODIFIED="2013-01-18 10:25:41 -0430" MODIFIED_BY="[Empty name]" NAME="Jaworski 2008" TYPE="JOURNAL_ARTICLE">
<AU>Jaworski J, Maslinski W, Pazdur J, Sliwinska-Stanczyk P, Kaminska-Tchorzewska E, Jung L, et al</AU>
<TI>Decreased expression of integrins by hematopoietic cells in patients with rheumatoid arthritis and anemia: relationship with bone marrow cytokine levels</TI>
<SO>Journal of Investigational Allergology &amp; Clinical Immunology</SO>
<YR>2008</YR>
<VL>18</VL>
<PG>17-21</PG>
<IDENTIFIERS MODIFIED="2010-01-29 13:47:39 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 13:47:39 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18361097"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jayaranee-2009" MODIFIED="2010-01-25 21:31:48 -0430" MODIFIED_BY="[Empty name]" NAME="Jayaranee 2009" TYPE="JOURNAL_ARTICLE">
<AU>Jayaranee S, Sthaneshwar P, Sokkalingam S</AU>
<TI>Serum prohepcidin concentrations in rheumatoid arthritis</TI>
<SO>Pathology</SO>
<YR>2009</YR>
<VL>41</VL>
<PG>178-82</PG>
<IDENTIFIERS MODIFIED="2010-01-25 21:31:48 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 21:31:48 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18972320"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kirkham-2010" MODIFIED="2013-01-22 13:10:49 -0430" MODIFIED_BY="[Empty name]" NAME="Kirkham 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al</AU>
<TI>The impact of outcome reporting bias in randomized controlled trials on a cohort of systematic reviews</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c365</PG>
<IDENTIFIERS MODIFIED="2012-01-23 14:42:07 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-23 14:42:07 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20156912"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kirwan-2007" MODIFIED="2013-01-22 13:10:59 -0430" MODIFIED_BY="[Empty name]" NAME="Kirwan 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kirwan JR, Minnock P, Adebajo A, Bresnihan B, Choy E, de Wit M, et al</AU>
<TI>Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2007</YR>
<VL>34</VL>
<PG>1174-7</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:37:17 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:37:17 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17477482"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kishimoto-2006" MODIFIED="2010-01-29 11:34:50 -0430" MODIFIED_BY="[Empty name]" NAME="Kishimoto 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kishimoto T</AU>
<TI>Interleukin-6: from basic science to medicine--40 years in immunology</TI>
<SO>Annual Review of Immunology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>1-21</PG>
<IDENTIFIERS MODIFIED="2010-01-29 11:34:17 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 11:34:17 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15771564 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krantz-1990" MODIFIED="2010-02-01 16:52:40 -0430" MODIFIED_BY="[Empty name]" NAME="Krantz 1990" TYPE="JOURNAL_ARTICLE">
<AU>Krantz SB, Sawyer ST, Sawada K, Wolfe F, Bocagno J</AU>
<TI>Erythropoietin: receptors and clinical use in rheumatoid arthritis</TI>
<SO>International Journal of Cell Cloning</SO>
<YR>1990</YR>
<VL>8 (Suppl 1)</VL>
<PG>181-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lee-2001" MODIFIED="2010-01-22 13:20:09 -0430" MODIFIED_BY="[Empty name]" NAME="Lee 2001" TYPE="JOURNAL_ARTICLE">
<AU>Lee DM, Weinblatt ME</AU>
<TI>Rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<PG>903-11</PG>
<IDENTIFIERS MODIFIED="2010-01-22 13:20:09 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 13:20:09 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11567728"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-2009" MODIFIED="2010-01-25 22:40:35 -0430" MODIFIED_BY="[Empty name]" NAME="Lee 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lee PL, Beutler E</AU>
<TI>Regulation of hepcidin and iron-overload disease</TI>
<SO>Annual Review of Pathology</SO>
<YR>2009</YR>
<VL>4</VL>
<PG>489-515</PG>
<IDENTIFIERS MODIFIED="2010-01-25 22:40:35 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 22:40:35 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19400694"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Macdougall-2005" MODIFIED="2010-01-29 14:30:52 -0430" MODIFIED_BY="[Empty name]" NAME="Macdougall 2005" TYPE="JOURNAL_ARTICLE">
<AU>Macdougall IC, Cooper AC</AU>
<TI>Hyporesponsiveness to erythropoietic therapy due to chronic inflammation</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>2005</YR>
<VL>35 (Suppl 3)</VL>
<PG>32-5</PG>
<IDENTIFIERS MODIFIED="2010-01-29 14:23:43 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 14:23:43 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16281956"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Masson-2011" MODIFIED="2012-07-28 12:58:56 -0430" MODIFIED_BY="[Empty name]" NAME="Masson 2011" TYPE="JOURNAL_ARTICLE">
<AU>Masson C</AU>
<TI>Rheumatoid anemia</TI>
<SO>Joint, Bone, Spine</SO>
<YR>2011</YR>
<VL>78</VL>
<NO>2</NO>
<PG>131-7</PG>
<IDENTIFIERS MODIFIED="2012-01-24 12:44:21 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20851655"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Maxwell-2009" MODIFIED="2012-12-18 16:06:13 -0430" MODIFIED_BY="[Empty name]" NAME="Maxwell 2009" TYPE="COCHRANE_REVIEW">
<AU>Maxwell L, Singh JA</AU>
<TI>Abatacept for rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:06:13 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:06:13 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007277.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McInnes-2011" MODIFIED="2012-01-24 12:40:56 -0430" MODIFIED_BY="[Empty name]" NAME="McInnes 2011" TYPE="JOURNAL_ARTICLE">
<AU>McInnes IB, Schett G</AU>
<TI>The pathogenesis of rheumatoid arthritis</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>365</VL>
<NO>23</NO>
<PG>2205-19</PG>
<IDENTIFIERS MODIFIED="2012-01-24 12:40:05 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="22150039"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Means-1995" MODIFIED="2010-01-26 00:56:35 -0430" MODIFIED_BY="[Empty name]" NAME="Means 1995" TYPE="JOURNAL_ARTICLE">
<AU>Means RT</AU>
<TI>Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia</TI>
<SO>Stem Cells</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>32-7</PG>
<IDENTIFIERS MODIFIED="2010-01-26 00:56:24 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-26 00:56:24 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7719246"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mertens-2009" MODIFIED="2012-12-18 16:13:07 -0430" MODIFIED_BY="[Empty name]" NAME="Mertens 2009" TYPE="COCHRANE_REVIEW">
<AU>Mertens M, Singh JA</AU>
<TI>Anakinra for rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:13:07 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:13:07 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005121.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Michaud-2007" MODIFIED="2010-01-22 13:35:21 -0430" MODIFIED_BY="[Empty name]" NAME="Michaud 2007" TYPE="JOURNAL_ARTICLE">
<AU>Michaud K, Wolfe F</AU>
<TI>Comorbidities in rheumatoid arthritis</TI>
<SO>Best Practice &amp; Research. Clinical Rheumatology</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>885-906</PG>
<IDENTIFIERS MODIFIED="2010-01-22 13:34:58 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 13:34:58 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17870034"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2013-01-22 13:11:19 -0430" MODIFIED_BY="[Empty name]" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomized trials</TI>
<SO>BMJ</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c869</PG>
<IDENTIFIERS MODIFIED="2012-01-23 14:04:33 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-01-23 14:04:33 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20332511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moreland-2009" MODIFIED="2010-01-29 13:58:15 -0430" MODIFIED_BY="[Empty name]" NAME="Moreland 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moreland LW, Curtis JR</AU>
<TI>Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2009</YR>
<VL>39</VL>
<PG>132-43</PG>
<IDENTIFIERS MODIFIED="2010-01-29 13:57:56 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 13:57:56 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19022481"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mu_x00f1_oz-2009" MODIFIED="2010-01-25 21:18:05 -0430" MODIFIED_BY="[Empty name]" NAME="Muñoz 2009" TYPE="JOURNAL_ARTICLE">
<AU>Muñoz M, Villar I, García-Erce JA</AU>
<TI>An update on iron physiology</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2009</YR>
<VL>15</VL>
<PG>4617-26</PG>
<IDENTIFIERS MODIFIED="2010-01-25 21:18:05 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 21:18:05 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19787824 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Navarro_x002d_Sarabia-2005" MODIFIED="2012-12-18 16:18:05 -0430" MODIFIED_BY="[Empty name]" NAME="Navarro-Sarabia 2005" TYPE="COCHRANE_REVIEW">
<AU>Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I</AU>
<TI>Adalimumab for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:18:05 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:18:05 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005113.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nebeker-2004" MODIFIED="2010-01-20 16:31:50 -0430" MODIFIED_BY="[Empty name]" NAME="Nebeker 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nebeker JR, Barach P, Samore MH</AU>
<TI>Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<PG>795-801</PG>
<IDENTIFIERS MODIFIED="2010-01-20 16:31:50 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-20 16:31:50 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15148066"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nemeth-2003" MODIFIED="2010-01-25 22:36:00 -0430" MODIFIED_BY="[Empty name]" NAME="Nemeth 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nemeth E, Ganz T</AU>
<TI>The role of hepcidin in iron metabolism</TI>
<SO>Acta Haematologica</SO>
<YR>2003</YR>
<VL>122</VL>
<PG>78-86</PG>
<IDENTIFIERS MODIFIED="2010-01-25 22:01:35 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 22:01:35 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19907144 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nemeth-2004" MODIFIED="2013-01-22 13:11:38 -0430" MODIFIED_BY="[Empty name]" NAME="Nemeth 2004" TYPE="JOURNAL_ARTICLE">
<AU>Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al</AU>
<TI>IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>2004</YR>
<VL>113</VL>
<PG>1271-6</PG>
<IDENTIFIERS MODIFIED="2010-01-25 23:02:52 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 23:02:52 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15124018"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nicolaisen-2008" MODIFIED="2010-01-29 16:57:30 -0430" MODIFIED_BY="[Empty name]" NAME="Nicolaisen 2008" TYPE="JOURNAL_ARTICLE">
<AU>Nikolaisen C, Figenschau Y, Nossent JC</AU>
<TI>Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality</TI>
<SO>Journal of Rheumatology</SO>
<YR>2008</YR>
<VL>35</VL>
<PG>380-6</PG>
<IDENTIFIERS MODIFIED="2010-01-29 13:23:52 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 13:23:52 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18260177"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Papadaki-2002" MODIFIED="2013-01-22 13:11:51 -0430" MODIFIED_BY="[Empty name]" NAME="Papadaki 2002" TYPE="JOURNAL_ARTICLE">
<AU>Papadaki HA, Kritikos HD, Gemetzi C, Koutala H, Marsh JC, Boumpas DT, et al</AU>
<TI>Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>99</VL>
<PG>1610-9</PG>
<IDENTIFIERS MODIFIED="2010-01-29 13:16:31 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 13:16:31 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11861275"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paulus-1990" MODIFIED="2011-04-04 09:15:04 -0430" MODIFIED_BY="[Empty name]" NAME="Paulus 1990" TYPE="JOURNAL_ARTICLE">
<AU>Paulus HE, Egger MJ, Ward JR, Williams HJ</AU>
<TI>Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group</TI>
<SO>Arthritis and rheumatism</SO>
<YR>1990</YR>
<VL>33</VL>
<NO>4</NO>
<PG>477-84</PG>
<IDENTIFIERS MODIFIED="2011-04-01 21:44:58 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="2109613"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-PCORI-2012" MODIFIED="2012-07-28 12:58:13 -0430" MODIFIED_BY="[Empty name]" NAME="PCORI 2012" TYPE="OTHER">
<AU>Patient-Centered Outcomes Research Institute (PCORI)</AU>
<TI>Preliminary draft methodology report: &#8220;Our questions, our decisions: Standards for patient&#8208;centered outcomes research&#8221;</TI>
<SO>http://www.pcori.org/assets/Preliminary-Draft-Methodology-Report.pdf</SO>
<YR>(accessed 27 July 2012)</YR>
<PG>1-61</PG>
<IDENTIFIERS MODIFIED="2012-07-28 12:58:13 -0430" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Pettersson-1993" MODIFIED="2010-02-01 15:56:36 -0430" MODIFIED_BY="[Empty name]" NAME="Pettersson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Pettersson T, Rosenlöf K, Friman C, Mickos A, Teppo AM, Fyhrquist F</AU>
<TI>Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>193</YR>
<VL>22</VL>
<PG>188-93</PG>
<IDENTIFIERS MODIFIED="2010-02-01 15:55:44 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-01 15:55:44 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8356412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pettersson-1994" MODIFIED="2010-02-01 15:46:06 -0430" MODIFIED_BY="[Empty name]" NAME="Pettersson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Pettersson T, Rosenlöf K, Laitinen E, Tenhunen R</AU>
<TI>Effect of exogenous erythropoietin on haem synthesis in anaemic patients with rheumatoid arthritis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>33</VL>
<PG>526-9</PG>
<IDENTIFIERS MODIFIED="2010-02-01 15:45:00 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-01 15:45:00 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8205399"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Porta-2008" MODIFIED="2010-01-20 16:22:00 -0430" MODIFIED_BY="[Empty name]" NAME="Porta 2008" TYPE="BOOK">
<AU>Porta M</AU>
<SO>A Dictionary of Epidemiology</SO>
<YR>2008</YR>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS MODIFIED="2010-01-20 16:21:17 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-20 16:21:17 -0430" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=" ISBN 978-0-19-531449-6"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Raj-2009" MODIFIED="2010-01-29 15:04:20 -0430" MODIFIED_BY="[Empty name]" NAME="Raj 2009" TYPE="JOURNAL_ARTICLE">
<AU>Raj DS</AU>
<TI>Role of interleukin-6 in the anemia of chronic disease</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>2009</YR>
<VL>38</VL>
<PG>382-8</PG>
<IDENTIFIERS MODIFIED="2010-01-29 15:04:19 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 15:04:19 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18336871"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2013-01-21 14:36:36 -0430" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre: The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roy-2005" MODIFIED="2010-01-25 22:50:47 -0430" MODIFIED_BY="[Empty name]" NAME="Roy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Roy CN, Andrews NC</AU>
<TI>Anemia of inflammation: the hepcidin link</TI>
<SO>Current Opinion in Hematology</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>105-11</PG>
<IDENTIFIERS MODIFIED="2010-01-25 22:50:47 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 22:50:47 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15725899"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ruiz-Garcia-2011" MODIFIED="2013-01-21 14:36:48 -0430" MODIFIED_BY="[Empty name]" NAME="Ruiz Garcia 2011" TYPE="COCHRANE_REVIEW">
<AU>Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Gálvez Muñoz JG, Saiz Cuenca ESC, et al</AU>
<TI>Certolizumab pegol (CDP870) for rheumatoid arthritis in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:26:29 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:26:29 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007649.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sasu-2010" MODIFIED="2013-01-21 14:37:11 -0430" MODIFIED_BY="[Empty name]" NAME="Sasu 2010" TYPE="JOURNAL_ARTICLE">
<AU>Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al</AU>
<TI>Anti-hepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia</TI>
<SO>Blood</SO>
<YR>2010</YR>
<VL>115</VL>
<NO>17</NO>
<PG>3616-24</PG>
<IDENTIFIERS MODIFIED="2010-01-25 23:10:27 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 23:10:27 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20053755"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2009" MODIFIED="2013-01-21 14:37:22 -0430" MODIFIED_BY="[Empty name]" NAME="Singh 2009" TYPE="COCHRANE_REVIEW">
<AU>Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al</AU>
<TI>Biologics for rheumatoid arthritis: an overview of Cochrane reviews</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:10:55 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:10:55 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007848.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2010a" MODIFIED="2012-12-18 16:34:25 -0430" MODIFIED_BY="[Empty name]" NAME="Singh 2010a" TYPE="COCHRANE_REVIEW">
<AU>Singh JA, Noorbaloochi S, Singh G</AU>
<TI>Golimumab for rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:23:53 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:23:53 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008341"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2010b" MODIFIED="2012-12-18 16:33:53 -0430" MODIFIED_BY="[Empty name]" NAME="Singh 2010b" TYPE="COCHRANE_REVIEW">
<AU>Singh JA, Beg S, Lopez-Olivo MA</AU>
<TI>Tocilizumab for rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:33:53 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:33:53 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008331.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Singh-2011" MODIFIED="2013-01-21 14:37:37 -0430" MODIFIED_BY="[Empty name]" NAME="Singh 2011" TYPE="COCHRANE_REVIEW">
<AU>Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, MacDonald JK, et al</AU>
<TI>Adverse effects of biologics: a network meta-analysis and Cochrane overview</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-12-18 16:08:20 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-12-18 16:08:20 -0430" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008794.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-1992" MODIFIED="2010-01-29 13:01:13 -0430" MODIFIED_BY="[Empty name]" NAME="Smith 1992" TYPE="JOURNAL_ARTICLE">
<AU>Smith MA, Knight SM, Maddison PJ, Smith JG</AU>
<TI>Anaemia of chronic disease in rheumatoid arthritis: effect of the blunted response to erythropoietin and of interleukin 1 production by marrow macrophages</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>1992</YR>
<VL>51</VL>
<PG>753-7</PG>
<IDENTIFIERS MODIFIED="2010-01-29 12:59:49 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 12:59:49 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1616358"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2013-01-21 14:37:48 -0430" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials</TI>
<SO>BMJ</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS MODIFIED="2012-07-26 14:26:14 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-26 14:26:14 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="21784880"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Theurl-2009" MODIFIED="2013-01-21 14:38:06 -0430" MODIFIED_BY="[Empty name]" NAME="Theurl 2009" TYPE="JOURNAL_ARTICLE">
<AU>Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al</AU>
<TI>Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications</TI>
<SO>Blood</SO>
<YR>2009</YR>
<VL>113</VL>
<PG>5277-86</PG>
<IDENTIFIERS MODIFIED="2010-01-25 21:21:52 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 21:21:52 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19293425 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2007" MODIFIED="2012-07-26 13:19:01 -0430" MODIFIED_BY="[Empty name]" NAME="Tugwell 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L</AU>
<TI>OMERACT: an international initiative to improve outcome measurement in rheumatology</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>38</PG>
<IDENTIFIERS MODIFIED="2012-07-26 13:18:59 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="18039364"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Turesson-2003" MODIFIED="2010-01-22 15:04:07 -0430" MODIFIED_BY="[Empty name]" NAME="Turesson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL</AU>
<TI>Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>62</VL>
<PG>722-7</PG>
<IDENTIFIERS MODIFIED="2010-01-22 15:04:07 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 15:04:07 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12860726"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Unger-2010" MODIFIED="2010-01-29 15:35:02 -0430" MODIFIED_BY="[Empty name]" NAME="Unger 2010" TYPE="JOURNAL_ARTICLE">
<AU>Unger EF, Thompson AM, Blank MJ, Temple R</AU>
<TI>Erythropoiesis-stimulating agents--time for a reevaluation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2010</YR>
<VL>362</VL>
<PG>189-92</PG>
<IDENTIFIERS MODIFIED="2010-01-29 15:34:03 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 15:34:03 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20054037"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-der-Putten-2008" MODIFIED="2012-03-02 13:47:31 -0430" MODIFIED_BY="[Empty name]" NAME="van der Putten 2008" TYPE="JOURNAL_ARTICLE">
<AU>van der Putten K, Braam B, Jie KE, Gaillard CA</AU>
<TI>Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure</TI>
<SO>Nature Clinical Practice. Nephrology</SO>
<YR>2008</YR>
<VL>4</VL>
<NO>1</NO>
<PG>47-57</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:47:31 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:47:31 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18094727"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vreugdenhil-1992a" MODIFIED="2010-02-01 16:03:54 -0430" MODIFIED_BY="[Empty name]" NAME="Vreugdenhil 1992a" TYPE="JOURNAL_ARTICLE">
<AU>Vreugdenhil G, Löwenberg B, Van Eijk HG, Swaak AJ</AU>
<TI>Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1992</YR>
<VL>22</VL>
<PG>488-93</PG>
<IDENTIFIERS MODIFIED="2010-01-29 11:47:15 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 11:47:15 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1516597"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vreugdenhil-1992b" MODIFIED="2010-02-01 16:01:59 -0430" MODIFIED_BY="[Empty name]" NAME="Vreugdenhil 1992b" TYPE="JOURNAL_ARTICLE">
<AU>Vreugdenhil G, Manger B, Nieuwenhuizen C, Feelders RA, van Eijk HG, Swaak AJ</AU>
<TI>Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis</TI>
<SO>Annals of Hematology</SO>
<YR>1992</YR>
<VL>65</VL>
<PG>265-8</PG>
<IDENTIFIERS MODIFIED="2010-02-01 16:01:40 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-01 16:01:40 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1457588"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weiss-2002" MODIFIED="2010-01-29 15:14:39 -0430" MODIFIED_BY="[Empty name]" NAME="Weiss 2002" TYPE="JOURNAL_ARTICLE">
<AU>Weiss G</AU>
<TI>Pathogenesis and treatment of anaemia of chronic disease</TI>
<SO>Blood Review</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>87-96</PG>
<IDENTIFIERS MODIFIED="2010-01-29 15:14:17 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 15:14:17 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12127952"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Weiss-2009" MODIFIED="2012-03-02 13:48:02 -0430" MODIFIED_BY="[Empty name]" NAME="Weiss 2009" TYPE="JOURNAL_ARTICLE">
<AU>Weiss G</AU>
<TI>Iron metabolism in the anemia of chronic disease</TI>
<SO>Biochimica et Biophysica Acta</SO>
<YR>2009</YR>
<VL>1790</VL>
<PG>682-93</PG>
<IDENTIFIERS MODIFIED="2012-03-02 13:48:02 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-02 13:48:02 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18786614"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-WHO-2008" MODIFIED="2010-01-22 14:20:58 -0430" MODIFIED_BY="[Empty name]" NAME="WHO 2008" TYPE="BOOK">
<AU>de Benoist B, McLean E, Egli I, Cogswell M, editors</AU>
<SO>Worldwide prevalence of anaemia 1993&#8211;2005 : WHO global database on anaemia</SO>
<YR>2008</YR>
<PB>World Health Organization</PB>
<CY>Geneva</CY>
<IDENTIFIERS MODIFIED="2010-01-22 14:07:12 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 14:07:12 -0430" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ISBN 978 92 4 159665 7"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2004" MODIFIED="2010-01-22 14:44:58 -0430" MODIFIED_BY="[Empty name]" NAME="Wilson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Wilson A, Yu HT, Goodnough LT, Nissenson AR</AU>
<TI>Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>116</VL>
<NO>Suppl 7A</NO>
<PG>50-7</PG>
<IDENTIFIERS MODIFIED="2010-01-22 14:44:58 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 14:44:58 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15050886 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wu-2003" MODIFIED="2010-01-29 13:51:36 -0430" MODIFIED_BY="[Empty name]" NAME="Wu 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wu HH, Talpaz M, Champlin RE, Pilat SR, Kurzrock R</AU>
<TI>Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses</TI>
<SO>Cancer</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>2410-9</PG>
<IDENTIFIERS MODIFIED="2010-01-29 13:51:36 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 13:51:36 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14635076"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Young-2007" MODIFIED="2010-01-22 15:34:50 -0430" MODIFIED_BY="[Empty name]" NAME="Young 2007" TYPE="JOURNAL_ARTICLE">
<AU>Young A, Koduri G</AU>
<TI>Extra-articular manifestations and complications of rheumatoid arthritis</TI>
<SO>Best Practice &amp; Reserach. Clinical Rheumatology</SO>
<YR>2007</YR>
<VL>21</VL>
<PG>907-27</PG>
<IDENTIFIERS MODIFIED="2010-01-22 15:33:41 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-22 15:33:41 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17870035"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2009" MODIFIED="2010-01-25 21:00:25 -0430" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" TYPE="OTHER">
<AU>Zhang AS, Enns CA</AU>
<TI>Molecular mechanisms of normal iron homeostasis</TI>
<SO>Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program</SO>
<YR>2009</YR>
<PG>207-14</PG>
<IDENTIFIERS MODIFIED="2010-01-25 21:00:15 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-25 21:00:15 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20008200"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zhu-2000" MODIFIED="2010-01-29 13:10:46 -0430" MODIFIED_BY="[Empty name]" NAME="Zhu 2000" TYPE="JOURNAL_ARTICLE">
<AU>Zhu Y, Ye D, Huang Z</AU>
<TI>The correlation of cytokines TNF alpha, IFN-gamma, Epo with anemia in rheumatoid arthritis</TI>
<SO>Zhonghua Xueyexue Zazhi</SO>
<YR>2000</YR>
<VL>21</VL>
<PG>587-90</PG>
<IDENTIFIERS MODIFIED="2010-01-29 13:09:29 -0430" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-29 13:09:29 -0430" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11225250 "/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2011-12-05 15:27:14 -0430" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-22 16:16:32 -0430" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-01-21 14:25:55 -0430" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-01-21 14:19:38 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<CHAR_METHODS MODIFIED="2013-01-21 14:18:06 -0430" MODIFIED_BY="[Empty name]">
<P>1. Design: parallel-design (2 arms)</P>
<P>2. Country: Sweden (7 sites)</P>
<P>3. Intention-to-treat analysis: no</P>
<P>4. Follow-up period: 12 weeks</P>
<P>5. Unit of randomization: patient</P>
<P>6. Unit of analysis: patient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-21 14:19:08 -0430" MODIFIED_BY="[Empty name]">
<P>1. Randomized: 46 (Quote "three active, one placebo") (page 68)<BR/>Erythropoietin (EPO) group: 36<BR/>Placebo group: 10</P>
<P>
<BR/>2. Patients receiving drug: 46<BR/>EPO group: 36 (78.2%)<BR/>Placebo group: 10 (21.7%)</P>
<P>
<BR/>3. Analyzed patients:<BR/>EPO group: 26 (72.2%)<BR/>Placebo group: 9 (90%)<BR/>Imbalance between groups: 17.8%</P>
<P>
<BR/>4. Age (years; mean±SD; range)<BR/>EPO group: 56.1±12.7; 25 to 76<BR/>Placebo group: 56.9±12.7; 29 to 79</P>
<P>
<BR/>5. Gender (female):<BR/>Overall: 85% (39/46)<BR/>EPO group: 80.5% (29/36)<BR/>Placebo group: 100% (10/10)</P>
<P>
<BR/>6. Inclusion criteria:</P>
<UL>
<LI>Clinical diagnosis of rheumatoid arthritis by American College of Rheumatology (ACR) criteria.</LI>
<LI>Independent of disease activity with stable disease.</LI>
<LI>The Disease-Modifying Anti-rheumatic Drugs (DMARDs) regimens unchanged during the treatment.</LI>
<LI>Hemoglobin concentrations below &#8804; 100 g/L (women) and &#8804; 110 g/L (men).</LI>
<LI>Hemoglobin concentrations during iron supplementations did not increase by more than 15 g/L.</LI>
</UL>
<P>7. Exclusion criteria:</P>
<UL>
<LI>Hemorrhage.</LI>
<LI>Hemolysis.</LI>
<LI>Folic acid deficiency.</LI>
<LI>Vitamin B<SUB>12</SUB> deficiency.</LI>
<LI>Uncontrolled hypertension.</LI>
<LI>Kidney disease.</LI>
<LI>Liver disease.</LI>
<LI>High doses of corticosteroids (exceeding 10 mg of prednisone or equivalent).</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-21 14:19:14 -0430" MODIFIED_BY="[Empty name]">
<OL>
<LI>Interventional group: recombinant human erythropoietin (rHuEPO; Express 10,000 U/ml, Cilag AB Sweden), 150 IU/ kg subcutaneous injected twice weekly. Duration: 12 weeks.</LI>
<LI>Placebo: subcutaneous injection twice weekly for 12 weeks. Nature of placebo: not given.</LI>
<LI>Co-intervention: oral iron supplementations at a median dose of 200 mg elemental iron per day.</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-21 14:19:26 -0430" MODIFIED_BY="[Empty name]">
<P>Outcomes were not defined explicitly as primary or secondary:</P>
<OL>
<LI>An adequate response was defined as reaching an Hb&#8805; 120 g/L at least once after the study start (page 68).</LI>
<LI>Elevation of energy level (page 70).</LI>
<LI>Safety (page 71).</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-21 14:19:38 -0430" MODIFIED_BY="[Empty name]">
<P>1. Sample size calculation a priori: not reported.<BR/>2. Sponsor: Cilag AB Sweden.<BR/>3. Roll of sponsor: not specified.</P>
<P>4. Conflict of interest: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-21 14:24:19 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peeters-1996">
<CHAR_METHODS MODIFIED="2013-01-21 14:21:22 -0430" MODIFIED_BY="[Empty name]">
<P>1. Design: parallel design (2 arms)<BR/>2. Country: Netherlands</P>
<P>3. Multicenter study: unclear.<BR/>4. Intention-to-treat analysis: yes<BR/>5. Per protocol analysis: yes<BR/>6. Follow-up period: 52 weeks</P>
<P>7. Unit of randomization: patient</P>
<P>8.Unit of analysis: patient</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-21 14:22:08 -0430" MODIFIED_BY="[Empty name]">
<P>1. Randomized: 70<BR/>Erythropoietin (EPO) group: 34<BR/>Placebo group: 36<BR/>
<BR/>
</P>
<P>2. Age: years; median 5th to 95th centile<BR/>EPO group: 56; 23 to 79<BR/>Placebo group: 58; 39 to 75</P>
<P>
<BR/>3. Gender (female):</P>
<P>EPO group: 79% (27/34)<BR/>Placebo group: 86% (31/36)<BR/>
<BR/>
</P>
<P>4. Inclusion criteria:</P>
<UL>
<LI>Age 18 years or older.</LI>
<LI>Clinical diagnosis of rheumatoid arthritis by American College of Rheumatology (ACR) criteria (functional class I, II, III). Active disease defined as a minimum of nine swollen joints and a Richie score of 9.</LI>
<LI>Anemia of chronic disease for a minimum duration of three months.</LI>
<LI>Hemoglobin concentrations below 117 g/L (for both men and women), without signs of vitamin and iron deficiency, blood loss, hemolysis, or other hematological disorder.</LI>
</UL>
<P>5. Exclusion criteria:</P>
<UL>
<LI>Patient receiving azathioprine, cyclophosphamide or cyclosporine</LI>
<LI>Signs of vitamin deficiency</LI>
<LI>Signs of iron deficiency</LI>
<LI>Blood loss</LI>
<LI>Hemolysis</LI>
<LI>Hematological disorders</LI>
<LI>History of thromboembolic events</LI>
<LI>History of epileptic fits</LI>
<LI>Uncontrolled hypertension</LI>
<LI>Renal disease</LI>
<LI>Liver disease</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-21 14:23:20 -0430" MODIFIED_BY="[Empty name]">
<P>1. Intervention group: recombinant human erythropoietin (rHuEPO ), 240 U per kg subcutaneous (sc) initially three times a week. Duration: 52 weeks.<BR/>
<BR/>
</P>
<P>2. Placebo: visually similar. Composition of placebo was not reported.<BR/>
<BR/>
</P>
<P>3. Co-intervention: oral iron supplementation.<BR/>
<BR/>
</P>
<P>Quote "Adjusment of the dose of disease modifying antirheumatic drugs or prednisone, as well as local measures, particularly intra-articular corticosteroids injections, was not allowed during the study (page 740)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-21 14:23:43 -0430" MODIFIED_BY="[Empty name]">
<P>1. Primary:</P>
<UL>
<LI>Hemoglobin measurements</LI>
<LI>Primary disease activity measure assessed by modified Paulus index (See <LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>)</LI>
</UL>
<P>2. Secondary:</P>
<UL>
<LI>Ritchie index</LI>
<LI>The number of swollen joints</LI>
<LI>Patient's global assessment</LI>
<LI>Westergren Erythro Sedimentation Rate</LI>
<LI>Pain score (1 to 10)</LI>
<LI>C-reactive protein concentration</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-21 14:24:19 -0430" MODIFIED_BY="[Empty name]">
<P>1. Sample size calculation a priori: not reported.<BR/>2. Sponsor: Dutch League against Rheumatism (Het Nationaal Rheuma Fonds).<BR/>3. Sponsor: Boehringer Mannheim provided rHuEPO.<BR/>4. Conflict of interest: not reported.</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-21 14:25:34 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pincus-1990">
<CHAR_METHODS MODIFIED="2013-01-21 14:24:51 -0430" MODIFIED_BY="[Empty name]">
<P>1. Design: parallel design (2 arms).<BR/>2. Multicenter study: USA (5 sites).<BR/>3. Intention-to-treat analysis: yes.<BR/>4. Follow-up period: 8 weeks.<BR/>5. Follow-up period: 24 weeks open label.</P>
<P>6.- Unit of randomization: patients</P>
<P>7.- Unit of analysis: patient.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-21 14:25:17 -0430" MODIFIED_BY="[Empty name]">
<P>1. Randomized: 17<BR/>Erythropoietin (EPO) group: 13<BR/>Placebo group:  4<BR/>
<BR/>2. Receiving EPO and placebo: 17<BR/>EPO group:13<BR/>Placebo group: 4</P>
<P>
<BR/>3. Age: years; mean range<BR/>
</P>
<P>Both groups: 52; 25 to 73<BR/>By comparison group: not reported<BR/>
</P>
<P>
<BR/>4. Gender (female):<BR/>Both group: 94.1% (16/17)</P>
<P>By comparison group: not reported</P>
<P>
<BR/>5. Inclusion criteria: These were not reported explicitly.</P>
<P>Quote: " All met the 1958 American Rheumatism Association criteria for rheumatoid arthritis... were being treated only with nonsteroidal anti-inflammatory drugs and no patient was taking gold, methotrexate, azathioprine, penicillamine, or prednisone, or had taken any second-line agents for 6 months prior to, or during, erythropoietin administration" (page 162).</P>
<P>
<BR/>6. Exclusion criteria:</P>
<UL>
<LI>Renal disease</LI>
<LI>History of seizure</LI>
<LI>Uncontrolled hypertension</LI>
<LI>Severe allergic reactions</LI>
<LI>Asthma</LI>
<LI>Active hepatitis</LI>
<LI>Other inflammatory conditions</LI>
<LI>Malignancy</LI>
<LI>Ischemic heart disease</LI>
<LI>Active peptic ulcer within one month of the study</LI>
<LI>Neutropenia</LI>
<LI>Hemolytic anemia</LI>
<LI>Thrombocytopenia</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-21 14:25:23 -0430" MODIFIED_BY="[Empty name]">
<P>1. Intervention group: recombinant human erythropoietin rHuEPO (50, 100, 150 U per kg three times a week, intravenous bolus given over a 5 minute period for up to 8 weeks).<BR/>
<BR/>
</P>
<P>2. Placebo: schedule identical to intervention. Placebo composition was not reported.</P>
<P>
<BR/>3. Co-intervention: oral ferrous sulphate (325 mg three times daily).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-21 14:25:27 -0430" MODIFIED_BY="[Empty name]">
<P>This trial did not explicitly address this domain.<BR/>
<BR/>
</P>
<P>1. Change in hematocrit, and leucocyte and platelet counts (page 163)<BR/>
<BR/>
</P>
<P>2. Safety (page 163)<BR/>
<BR/>
</P>
<P>3. Rheumatologic clinical status changes (page 165)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-21 14:25:34 -0430" MODIFIED_BY="[Empty name]">
<P>1. Sample size calculation a priori: not reported.<BR/>
<BR/>2. Sponsor: Ortho Biotech Corporation, National Institutes of Health (grants DK-1555, RR-95, and T32-07186), Jack C Massey Foundation, and Veterans Administration Medical Research Funds.<BR/>
<BR/>3. Role of sponsor: Ortho Biotech Corporation provided the intervention.</P>
<P>
<BR/>4.- This study had two phases:</P>
<P>First phase: 8 weeks randomized double blind study.</P>
<P>Second Phase: 24 week-open-label-study "involved an open-label protocol in which all patients received erythropoietin three times weekly" (page 163). Quote: "Following the 8 week randomized study, the 17 patients were offered the possibility of participations in a 24 week open-label extension study" (page 162).</P>
<P>
<BR/>5. Conflict of interest: not described.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-01-22 16:16:32 -0430" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-01-22 16:15:54 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arndt-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-22 16:15:54 -0430" MODIFIED_BY="[Empty name]">
<P>Clinical trial but not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:25:55 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Birgegard-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:25:55 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-22 16:16:03 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dyjas-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-22 16:16:03 -0430" MODIFIED_BY="[Empty name]">
<P>Controlled clinical trial but not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:25:57 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fantini-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:25:57 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:25:57 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goodnough-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:25:57 -0430" MODIFIED_BY="[Empty name]">
<P>Narrative review of the responses to erythropoietin in patients with rheumatoid arthritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-22 16:16:08 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaltwasser-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-22 16:16:08 -0430" MODIFIED_BY="[Empty name]">
<P>Clinical trial but not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-01 22:48:02 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kato-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-01 22:48:02 -0430" MODIFIED_BY="[Empty name]">
<P>Trial was conducted using historical controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-12-07 11:54:52 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krantz-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-12-07 11:54:52 -0430" MODIFIED_BY="[Empty name]">
<P>Narrative review of erythropoietin and the anemia of chronic disease</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-04-01 22:54:14 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matsuda-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-04-01 22:54:14 -0430" MODIFIED_BY="[Empty name]">
<P>Trial included patients without anemia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:00 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Means-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:00 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:01 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercuriali-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:01 -0430" MODIFIED_BY="[Empty name]">
<P>Narrative review of erythropoietin alpha for autologous blood donations in patients with rheumatoid arthritis and concomitant anemia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-31 16:33:03 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mercuriali-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-31 16:33:03 -0430" MODIFIED_BY="[Empty name]">
<P>Trial was conducted using historical controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:02 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:02 -0430" MODIFIED_BY="[Empty name]">
<P>This study is shown as RCT involving 20 participants (10 assigned to EPO versus 10 randomized to placebo).</P>
<P>Quote "Intervention group: recombinant human erythropoietin (rHuEPO) "starting at 40 IU per kg (patients <I>1-10</I>) and 100 U/Kg (patients <I>11-20</I>)" (page 1337), subcutaneous (sc), twice a week by 20 weeks".</P>
<P>Therefore, it must be considered as non-randomized.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:04 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettersson-1993a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:04 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:06 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saikawa-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:06 -0430" MODIFIED_BY="[Empty name]">
<P>Study including anemic and non-anemic with rheumatoid arthritis. All participants received erythropoietin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:08 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salvarani-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:08 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:08 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swaak-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:08 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-21 14:26:09 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Takashina-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-21 14:26:09 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-03-31 18:04:33 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tauchi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-03-31 18:04:33 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-06 07:16:32 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vreugdenhil-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-06 07:16:32 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-12-06 07:16:34 -0430" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vreugdenhil-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-12-06 07:16:34 -0430" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-04-01 22:56:28 -0430" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-03-02 08:23:14 -0430" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-01-21 14:25:55 -0430" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-01-21 14:25:42 -0430" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-05 04:27:29 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<DESCRIPTION>
<P>Quote: &#8220;Randomization was carried out in blocks of four patients (three active, one placebo) and allocation within each block was in random order&#8221; (page 68).</P>
<P>Insufficient information to consider 'low risk' or 'high risk'.</P>
<P>Comment: there is an imbalance in gender and duration of disease variables (page 69, table 1).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-05 04:42:03 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peeters-1996">
<DESCRIPTION>
<P>Quote " randomisation of the patients...was done by a second independent observer" (page 740).</P>
<P>Insufficient information to permit judgment of 'low risk' or 'high risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 14:25:42 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pincus-1990">
<DESCRIPTION>
<P>Insufficient information to consider 'low risk' or 'high risk'.<BR/>Comment: there is imbalance between comparison groups regarding treated number of patients (13 treated with EPO and 4 with placebo).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-01-21 14:25:48 -0430" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-05 04:27:31 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'low risk' or 'high risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 14:24:23 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Peeters-1996">
<DESCRIPTION>
<P>Quote: 'Randomisation of the patients ... was done by a second independent observer.'</P>
<P>Insufficient information to permit judgment of 'low risk' or 'high risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 14:25:48 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pincus-1990">
<DESCRIPTION>
<P>Insufficient information to consider 'low risk' or 'high risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-03-30 17:34:27 -0430" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-01-21 14:25:48 -0430" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-05 04:33:59 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'low risk' or 'high risk'.</P>
<P>This trial was reported as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-21 14:24:28 -0430" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-1996">
<DESCRIPTION>
<P>Quote: "The placebo group received a visually similar placebo. After randomisation, patients in the placebo group were matched with patients in the treatment group and followed their treatment regime with respect to frequency of administration".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2013-01-21 14:25:48 -0430" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pincus-1990">
<DESCRIPTION>
<P>Quote: "identically appearing placebo" (page 162)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2013-01-21 14:25:54 -0430" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-05 04:34:07 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<DESCRIPTION>
<P>Insufficient information to permit judgment of 'low risk' or 'high risk'.</P>
<P>This trial was reported as double-blind.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-05 04:43:32 -0430" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-1996">
<DESCRIPTION>
<P>Quote: "Disease activity measures were assessed by the first observer, who remained blinded for treatment schedules and laboratory results" (page 740).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-01-21 14:25:54 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pincus-1990">
<DESCRIPTION>
<P>Insufficient information to consider 'low risk' or 'high risk'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-01-21 14:24:31 -0430" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-21 14:19:55 -0430" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<DESCRIPTION>
<P>1. Lost postrandomization: 24% (11/46).<BR/>EPO group: 38.4% (10/26).<BR/>Placebo group: 11.1% (1/9).<BR/>
<BR/>2. Imbalance between comparison groups: 27.3%</P>
<P>
<BR/>Quote: "(5 patients excluded due to entering the extension study, 5 drop-outs) patients receiving rHuEPO over 9 patients receiving placebo (one drop out)" (page 70)</P>
<P>
<BR/>3. Comment: potentially inappropriate application of simple imputation.<BR/>
<BR/>
</P>
<P>4. Comment: For continuous outcome data, plausible effects size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size and potentially inappropriate application of simple imputation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-21 14:24:31 -0430" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Peeters-1996">
<DESCRIPTION>
<P>1. Overall: 82.8% (58/70)<BR/>2. EPO group: 85% (29/34)<BR/>3. Placebo group: 80% (29/36)</P>
<P>4. Imbalance between groups: 5%</P>
<P>
<BR/>Comment: Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. However, this was a small trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-22 12:14:21 -0430" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pincus-1990">
<DESCRIPTION>
<P>No missing outcome data.<BR/>
<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-01-21 14:25:55 -0430" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 14:20:41 -0430" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<DESCRIPTION>
<P>Quote: "A significant rise in Hb was noted in 26 (5 patients excluded due to entering the extension study, 5 drop-outs) patients receiving rHuEPO over 9 patients receiving placebo (one drop-out) (Hb elevation from 95 g/L to 107 g/L vs 93 g/L to 97 g/L, P &lt; 0.05), from week 10 onwards that lasted throughout the study. A significant elevation of red blood cells was noted already from 4 weeks onward (P = 0.02) and Hct levels at week 12 (P = 0.009)" (page 70)</P>
<P>Quote: "only 14.6% (N = 6) of the patients were considered responders according to the preset criteria of Hb level equaling or exceeding 120 g/l" (page 70).</P>
<P>Quote "A significant elevation of energy (NHP variable) was noted at the end of the study after week 12 (P = 0.004). Otherwise, HAQ scores, NHP scores, classification of functional class or joint score index scores did not differ significantly between the two groups". (page 70).</P>
<P>Comment: one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 14:24:38 -0430" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-1996">
<DESCRIPTION>
<P>This trial reported outcomes of clinical interest.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 14:25:55 -0430" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pincus-1990">
<DESCRIPTION>
<P>One or more outcomes of interest in the review are reported incompletely, so that they cannot be entered in a meta-analysis.</P>
<P>Comment: this trial reported only activities of daily living score and visual analog pain scale score data for intervention group. (page162).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-01-21 14:20:58 -0430" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-21 14:20:58 -0430" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nordstr_x00f6_m-1997">
<DESCRIPTION>
<P>Comments:</P>
<P>1. There is imbalance between comparison groups regarding gender, duration of disease (years) and medication for treating ARA variables (page 69).</P>
<P>2. There was a potential source of bias related to the specific study design used, with extreme baseline imbalance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-13 15:46:19 -0430" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Peeters-1996">
<DESCRIPTION>
<P>Quote: "At baseline, groups were compared using Student's t test, the Mann-Whitney test, and the x' test where appropriate."</P>
<P>There was no significant baseline imbalance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-12-13 15:48:23 -0430" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pincus-1990">
<DESCRIPTION>
<P>Comment: this trial did not report baseline characteristics of the patients assigned to placebo group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-01-21 14:33:40 -0430" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-01-21 14:33:40 -0430" MODIFIED_BY="Grade Profiler" NO="1" READONLY="YES">
<TITLE MODIFIED="2012-12-10 15:19:02 -0430" MODIFIED_BY="Grade Profiler">Erythropoietin (subcutaneous or intravenous at varying dosages) compared to placebo for anemia in patients with rheumatoid arthritis</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Erythropoietin (subcutaneous or intravenous at varying dosages) compared to placebo for anemia in patients with rheumatoid arthritis</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> anemia in patients with rheumatoid arthritis<BR/>
<B>Settings:</B> outpatient<BR/>
<B>Intervention:</B> erythropoietin (subcutaneous or intravenous at varying dosages)<BR/>
<B>Comparison: </B>placebo</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Placebo</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Erythropoietin (subcutaneous or intravenous at varying dosages)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Health-related quality of life</B>
<BR/>Follow-up: 8 to 52 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>136<BR/>(3 studies<SUP>1</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>, with 70 participants followed up during 52 weeks reporting patients' global assessment (VAS score 0 to 10), found statistically significant differences comparing EPO versus placebo (median and interquartile range at 52 weeks: 3.5 (1.0 to 6.0) and 4.5 (2.0 to 7.5) P = 0.027, respectively.</P>
<P/>
<P>
<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>, with 17 participants followed up during 8 weeks, reported no significant differences between groups of patient satisfaction in activities of daily living using the mHAQ<SUP>5 </SUP>but data were not provided.</P>
<P>
<BR/>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK>, with 46 participants followed up at 12 weeks, reported no significant difference between groups in Stanford Health Assessment Questionnaire scores, Nottingham Health Profile scores, classification of functional class or joint score index scores.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Hemoglobin (Hb) level at the end of the study</B>
<BR/>Follow-up: 12 to 52 weeks<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>116<BR/>(2 studies<SUP>4</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK> (46 participants) reported a statistically significant increase in hemoglobin level at 12 weeks in the EPO group compared with placebo group (MD 8.00, 95% CI 7.43 to 8.57 g/l; P = 0.00001) </P>
<P/>
<P>
<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK> (70 participants) reported a statistically significant increase in hemoglobin level at 52 weeks in the EPO group (median 134; interquartile range 110 to 158 g/L) compared with placebo group (median 112; interquartile range 86 to 128 g/L) (P = 0.001). </P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Fatigue</B>
</P>
<P>Not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>This outcome was not assessed by any of the trials.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Safety (Adverse events including adverse drug reaction)</B>
</P>
<P>Follow-up: 8 to 52 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>(3 studies<SUP>1</SUP>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK> found no significant alterations in pulse, blood pressure, platelet counts, albumin, creatinine, alanine aminotransferase, or aspartate aminotransferase values .<BR/>
<BR/>
<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK> assessed adverse events and found no significant rise in blood pressure and thromboembolic complications.<BR/>
</P>
<P>
<LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK> found no adverse reactions. </P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawals due to adverse events</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>
<LINK REF="STD-Nordstr_x00f6_m-1997" TYPE="STUDY">Nordström 1997</LINK> reported no serious adverse events causing premature discontinuation. This outcome was not reported by the other two trials (<LINK REF="STD-Peeters-1996" TYPE="STUDY">Peeters 1996</LINK>; <LINK REF="STD-Pincus-1990" TYPE="STUDY">Pincus 1990</LINK>).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawals due to lack of efficacy</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>This outcome was not assessed by any of the trials.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Withdrawals due to high blood pressure</B>
</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>See comment</P>
</TD>
<TD>
<P>This outcome was not assessed by any of the trials.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>1. Nordström 1997, Peeters 1996, Pincus 1990<BR/>2. Almost all domains had a high or unclear risk of bias.<BR/>3. Small sample size<BR/>4<SUP>.</SUP> Nordström 1997, Peeters 1996<BR/>5. mHAQ: modified Stanford Health Assessment Questionnaire<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-07-27 10:59:42 -0430" MODIFIED_BY="[Empty name]"/>
<FIGURES MODIFIED="2013-01-21 14:39:29 -0430" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-01-21 14:39:29 -0430" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram (7 August 2012).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAmgAAANLCAYAAAD1oGFlAACAAElEQVR42uy9DaRV2R///2WMjCSR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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-01-21 14:25:56 -0430" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-01-21 14:25:56 -0430" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUUAAAGvCAIAAABDyVDuAAATkElEQVR42u3dsY4cVRbG8ZGQEIED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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-11-22 16:17:06 -0430" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-11-22 16:16:44 -0430" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-01-20 12:26:04 -0430" MODIFIED_BY="[Empty name]">American Rheumatology criteria of rheumatoid arthritis</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-22 16:16:44 -0430" MODIFIED_BY="[Empty name]">
<P>Source: <LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK>
</P>
<OL>
<LI>Morning stiffness in and around joints lasting at least 1 hour before maximal improvement;</LI>
<LI>Soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician;</LI>
<LI>Swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or wrist joints;</LI>
<LI>Symmetric swelling (arthritis);</LI>
<LI>Rheumatoid nodules;</LI>
<LI>The presence of rheumatoid factor;</LI>
<LI>Radiographic erosions and/or periarticular osteopenia in hand and/or wrist joints.</LI>
</OL>
<P>
<BR/>Criteria 1 through 4 must have been present for at least 6 weeks.<BR/>Rheumatoid arthritis is defined by the presence of 4 or more criteria, and no further qualifications (classic, definite, or probable) or list of exclusions are required.</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-11-22 16:17:06 -0430" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-01-26 00:59:55 -0430" MODIFIED_BY="[Empty name]">World Health Organization</TITLE>
<APPENDIX_BODY MODIFIED="2012-11-22 16:17:06 -0430" MODIFIED_BY="[Empty name]">
<P>Source: <LINK REF="REF-WHO-2008" TYPE="REFERENCE">WHO 2008</LINK>
</P>
<P>2.1.- Hemoglobin: &lt;120 g/l (12 g/dl) for non-pregnant women (&#8805;15 years).</P>
<P>2.2.- Hemoglobin: &lt;130 g/l (13 g/dl) for men(&#8805;15 years).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-10-25 15:32:44 -0430" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-12-05 14:46:15 -0430" MODIFIED_BY="[Empty name]">Ovid Medline search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-05 14:46:23 -0430" MODIFIED_BY="[Empty name]">
<P>1. exp arthritis, rheumatoid/</P>
<P>2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$ or artrit$ or diseas$ or condition$ or nodule$)).tw.</P>
<P>3. (felty$ adj2 syndrome).tw.</P>
<P>4. (caplan$ adj2 syndrome).tw.</P>
<P>5. (sjogren$ adj2 syndrome).tw.</P>
<P>6. (sicca adj2 syndrome).tw.</P>
<P>7. still$ disease.tw.</P>
<P>8. bechterew$ disease.tw.</P>
<P>9. or/1-8</P>
<P>10. exp Hematinics/</P>
<P>11. hematinic$.tw.</P>
<P>12. hematopoietic$.tw.</P>
<P>13. erythropoie$.tw.</P>
<P>14. (esa or esas).tw.</P>
<P>15. rhuepo.tw.</P>
<P>16. (epoetin adj (alpha or alfa or beta)).tw.</P>
<P>17. Abseamed.tw.</P>
<P>18. Binocrit.tw.</P>
<P>19. Culat.tw.</P>
<P>20. Dynepo.tw.</P>
<P>21. EPIAO.tw.</P>
<P>22. Epog?en.tw.</P>
<P>23. Epokine.tw.</P>
<P>24. Epomax.tw.</P>
<P>25. Epopen.tw.</P>
<P>26. Eporon.tw.</P>
<P>27. Eposino.tw.</P>
<P>28. Epotin.tw.</P>
<P>29. Epotrex.tw.</P>
<P>30. Epovitan.tw.</P>
<P>31. Epoxitin.tw.</P>
<P>32. Eprex.tw.</P>
<P>33. Erantin.tw.</P>
<P>34. Eritina.tw.</P>
<P>35. Eritrogen.tw.</P>
<P>36. Eritromax.tw.</P>
<P>37. Erypo.tw.</P>
<P>38. Exetin-A.tw.</P>
<P>39. Globuren.tw.</P>
<P>40. Hemapo.tw.</P>
<P>41. Hemax-Eritron.tw.</P>
<P>42. Hemax.tw.</P>
<P>43. Hemoprex.tw.</P>
<P>44. Hepta.tw.</P>
<P>45. Hypercrit.tw.</P>
<P>46. Mepotin.tw.</P>
<P>47. Mircera.tw.</P>
<P>48. Negortire.tw.</P>
<P>49. NeoRecormon.tw.</P>
<P>50. Procrit.tw.</P>
<P>51. Recormon.tw.</P>
<P>52. Renogen.tw.</P>
<P>53. Repotin.tw.</P>
<P>54. Retacrit.tw.</P>
<P>55. Silapo.tw.</P>
<P>56. Tinax.tw.</P>
<P>57. Wepox.tw.</P>
<P>58. Yepotin.tw.</P>
<P>59. or/10-58</P>
<P>60. randomized controlled trial.pt.</P>
<P>61. controlled clinical trial.pt.</P>
<P>62. randomized.ab.</P>
<P>63. placebo.ab.</P>
<P>64. drug therapy.fs.</P>
<P>65. randomly.ab.</P>
<P>66. trial.ab.</P>
<P>67. groups.ab.</P>
<P>68. or/60-67</P>
<P>69. (animals not (humans and animals)).sh.</P>
<P>70. 68 not 69</P>
<P>71. and/9,59,70</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2012-10-25 15:32:47 -0430" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2011-12-05 14:46:58 -0430" MODIFIED_BY="[Empty name]">Ovid EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-05 14:47:02 -0430" MODIFIED_BY="[Empty name]">
<P>1. exp arthritis, rheumatoid/</P>
<P>2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$ or artrit$ or diseas$ or condition$ or nodule$)).tw.</P>
<P>3. (felty$ adj2 syndrome).tw.</P>
<P>4. (caplan$ adj2 syndrome).tw.</P>
<P>5. (sjogren$ adj2 syndrome).tw.</P>
<P>6. (sicca adj2 syndrome).tw.</P>
<P>7. still$ disease.tw.</P>
<P>8. or/1-7</P>
<P>9. exp antianemic agent/</P>
<P>10. hematinic$.tw.</P>
<P>11. hematopoietic$.tw.</P>
<P>12. erythropoie$.tw.</P>
<P>13. (esa or esas).tw.</P>
<P>14. rhuepo.tw.</P>
<P>15. (epoetin adj (alpha or alfa or beta)).tw.</P>
<P>16. Abseamed.tw.</P>
<P>17. Binocrit.tw.</P>
<P>18. Culat.tw.</P>
<P>19. Dynepo.tw.</P>
<P>20. EPIAO.tw.</P>
<P>21. Epog?en.tw.</P>
<P>22. Epokine.tw.</P>
<P>23. Epomax.tw.</P>
<P>24. Epopen.tw.</P>
<P>25. Eporon.tw.</P>
<P>26. Eposino.tw.</P>
<P>27. Epotin.tw.</P>
<P>28. Epotrex.tw.</P>
<P>29. Epovitan.tw.</P>
<P>30. Epoxitin.tw.</P>
<P>31. Eprex.tw.</P>
<P>32. Erantin.tw.</P>
<P>33. Eritina.tw.</P>
<P>34. Eritrogen.tw.</P>
<P>35. Eritromax.tw.</P>
<P>36. Erypo.tw.</P>
<P>37. Exetin-A.tw.</P>
<P>38. Globuren.tw.</P>
<P>39. Hemapo.tw.</P>
<P>40. Hemax-Eritron.tw.</P>
<P>41. Hemax.tw.</P>
<P>42. Hemoprex.tw.</P>
<P>43. Hepta.tw.</P>
<P>44. Hypercrit.tw.</P>
<P>45. Mepotin.tw.</P>
<P>46. Mircera.tw.</P>
<P>47. Negortire.tw.</P>
<P>48. NeoRecormon.tw.</P>
<P>49. Procrit.tw.</P>
<P>50. Recormon.tw.</P>
<P>51. Renogen.tw.</P>
<P>52. Repotin.tw.</P>
<P>53. Retacrit.tw.</P>
<P>54. Silapo.tw.</P>
<P>55. Tinax.tw.</P>
<P>56. Wepox.tw.</P>
<P>57. Yepotin.tw.</P>
<P>58. or/9-57</P>
<P>59. 8 and 58</P>
<P>60. (random$ or placebo$).ti,ab.</P>
<P>61. ((single$ or double$ or triple$ or treble$) and (blind$ or mask$)).ti,ab.</P>
<P>62. controlled clinical trial$.ti,ab.</P>
<P>63. RETRACTED ARTICLE/</P>
<P>64. or/60-63</P>
<P>65. (animal$ not human$).sh,hw.</P>
<P>66. 64 not 65</P>
<P>67. 59 and 66</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2012-10-25 15:32:50 -0430" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-12-05 14:47:37 -0430" MODIFIED_BY="[Empty name]">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-11 08:52:47 -0430" MODIFIED_BY="[Empty name]">
<P>rheumatoid OR rheumatoid OR revmatoid OR rheumatic OR rheumatic OR revmatic OR reumat* OR revmarthrit* in Words</P>
<P>AND</P>
<P>hematinic* hematopoietic* or erythropoie* or rhuepo or epoetin in Words</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2012-10-25 15:32:54 -0430" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-12-05 14:48:08 -0430" MODIFIED_BY="[Empty name]">Scopus search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-05 14:48:12 -0430" MODIFIED_BY="[Empty name]">
<P>#1 rheumatoid OR rheumatoid OR revmatoid OR rheumatic OR rheumatic OR revmatic OR reumat* OR revmarthrit*in TITLE-ABS-KEY</P>
<P>#2 hematinic* OR hematopoietic*OR erythropoie* OR rhuepo OR epoetin in TITLE-ABS-KEY</P>
<P>#3 #1 AND #2</P>
<P>#4 #3 limited to Conference Paper</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2012-10-25 15:32:57 -0430" MODIFIED_BY="[Empty name]" NO="7">
<TITLE MODIFIED="2011-12-05 14:48:26 -0430" MODIFIED_BY="[Empty name]">World Health Organization International Clinical Trials Registry Platform</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-05 14:48:37 -0430" MODIFIED_BY="[Empty name]">
<P>#1 rheumatoid OR rheumatoid OR revmatoid OR rheumatic OR rheumatic OR revmatic OR reumat* OR revmarthrit*in Condition</P>
<P>#2 hematinic* OR hematopoietic*OR erythropoie* OR rhuepo OR epoetin in Intervention</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2012-10-25 15:33:00 -0430" MODIFIED_BY="[Empty name]" NO="8">
<TITLE MODIFIED="2011-12-05 14:49:08 -0430" MODIFIED_BY="[Empty name]">Ovid EBM Reviews</TITLE>
<APPENDIX_BODY MODIFIED="2011-12-05 14:49:29 -0430" MODIFIED_BY="[Empty name]">
<P>1. exp arthritis, rheumatoid/</P>
<P>2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$ or artrit$ or diseas$ or condition$ or nodule$)).tw.</P>
<P>3. (felty$ adj2 syndrome).tw.</P>
<P>4. (caplan$ adj2 syndrome).tw.</P>
<P>5. (sjogren$ adj2 syndrome).tw.</P>
<P>6. (sicca adj2 syndrome).tw.</P>
<P>7. still$ disease.tw.</P>
<P>8. bechterew$ disease.tw.</P>
<P>9. or/1-8</P>
<P>10. exp Hematinics/</P>
<P>11. hematinic$.tw.</P>
<P>12. hematopoietic$.tw.</P>
<P>13. erythropoie$.tw.</P>
<P>14. (esa or esas).tw.</P>
<P>15. rhuepo.tw.</P>
<P>16. (epoetin adj (alpha or alfa or beta)).tw.</P>
<P>17. Abseamed.tw.</P>
<P>18. Binocrit.tw.</P>
<P>19. Culat.tw.</P>
<P>20. Dynepo.tw.</P>
<P>21. EPIAO.tw.</P>
<P>22. Epog?en.tw.</P>
<P>23. Epokine.tw.</P>
<P>24. Epomax.tw.</P>
<P>25. Epopen.tw.</P>
<P>26. Eporon.tw.</P>
<P>27. Eposino.tw.</P>
<P>28. Epotin.tw.</P>
<P>29. Epotrex.tw.</P>
<P>30. Epovitan.tw.</P>
<P>31. Epoxitin.tw.</P>
<P>32. Eprex.tw.</P>
<P>33. Erantin.tw.</P>
<P>34. Eritina.tw.</P>
<P>35. Eritrogen.tw.</P>
<P>36. Eritromax.tw.</P>
<P>37. Erypo.tw.</P>
<P>38. Exetin-A.tw.</P>
<P>39. Globuren.tw.</P>
<P>40. Hemapo.tw.</P>
<P>41. Hemax-Eritron.tw.</P>
<P>42. Hemax.tw.</P>
<P>43. Hemoprex.tw.</P>
<P>44. Hepta.tw.</P>
<P>45. Hypercrit.tw.</P>
<P>46. Mepotin.tw.</P>
<P>47. Mircera.tw.</P>
<P>48. Negortire.tw.</P>
<P>49. NeoRecormon.tw.</P>
<P>50. Procrit.tw.</P>
<P>51. Recormon.tw.</P>
<P>52. Renogen.tw.</P>
<P>53. Repotin.tw.</P>
<P>54. Retacrit.tw.</P>
<P>55. Silapo.tw.</P>
<P>56. Tinax.tw.</P>
<P>57. Wepox.tw.</P>
<P>58. Yepotin.tw.</P>
<P>59. or/10-58</P>
<P>71. 9 and 59</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2012-10-25 15:33:33 -0430" MODIFIED_BY="[Empty name]" NO="9">
<TITLE MODIFIED="2011-04-01 21:44:18 -0430" MODIFIED_BY="[Empty name]">Modified Paulus index</TITLE>
<APPENDIX_BODY MODIFIED="2012-10-25 15:33:33 -0430" MODIFIED_BY="[Empty name]">
<P>From <LINK REF="REF-Paulus-1990" TYPE="REFERENCE">Paulus 1990</LINK>.</P>
<OL>
<LI>Ritchie index;</LI>
<LI>Number of swollen joints;</LI>
<LI>Duration of morning stiffness;</LI>
<LI>Patients' assessment of disease activity;</LI>
<LI>Observers' assessment of disease activity;</LI>
<LI>Erythrocyte sedimentation rate.</LI>
</OL>
<P>If responses in 4 of 6 selected measures were required for improvement (greater than or equal to 20% of above criteria), and by greater than or equal to 2 grades on a 5-grade scale, or from grade 2 to grade 1 for patient's and physician's overall assessments of current disease severity).</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2012-03-02 08:23:17 -0430" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;No trials included in quantitative synthesis (meta analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;3 trials included&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;24 full text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;337 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;337 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;403 records identified through database searching&lt;br&gt;&lt;/p&gt;&lt;p&gt;MEDLINE (Ovid) and Ovid MEDLINE(R) In Process &amp;amp; Other Non Indexed Citations (N = 176); Embase (Ovid) (N = 80); All accessed via Ovid CENTRAL, part of The Cochrane Library (N = 45); DARE, part of The Cochrane Library (N = 1); HTA Database, part of The Cochrane Library (N = 1); NHS EED, part of The Cochrane Library (N = 0); LILACS ( N = 0); Scopus (N = 100).&lt;/p&gt;" WIDTH="386"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 records identified through other sources:&lt;br&gt;World Health Organization International Clinical Trials Registry Platform.&lt;br&gt;&lt;/p&gt;" WIDTH="178"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;314 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;21 full text articles excluded, with reasons&lt;br&gt;Clinical trial (3); narrative review (3); trial using historical controls (2); cases report (10); other reasons (3).&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>